var title_f24_44_25280="Approach to diagnosis of mast cell disorders";
var content_f24_44_25280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Approach to diagnosis of mast cell disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 619px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25280=[""].join("\n");
var outline_f24_44_25280=null;
var title_f24_44_25281="Churg Strauss lateral";
var content_f24_44_25281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 289px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEhAO0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dvZHa4lRnYqHOATwOar1Ld/8fc3++386ioAKKWigBKWiigAooooAKMUtFACr1Fe2fDSyhvtNhaa2ibtvMYOeO9eNWFrLeXKQwKWdjgBRmvo/4b6aLCwhSQYbAypHTigDt9N0SzEQxaQf9+h/hWtFpFnn/j0gJH/TIf4Vd02DcgwOPp7VsxWncj8MUAY0Gl2yZEdtCo/2YwKtpp8YIIjUEdDtraS2A4x+lTi3HpQBifZ3TG1mprxynP7xx36mt17bnpzn0pr2h64/SgDmpopcY8yT8zVCaGY/8tJPzNda9oOw5+lVns/UY/CgDiLq2kKn95J+Zrm9bspJI2UO+evU16TdWQwf8Kw76xyDx+lAHgnibTGO/Ib6V5pqNm0Usgwcc9RX0V4k0wM0hA7H+GvLtd0bJlYLkYP8NAHmcEZe4jT+8wFRt9446ZrSZJbLUoyke6QPgKVznPHA79aqX7BrhsRomDghU289+MmgCvT1nlRdqSuqjsGIFMptAE32mf8A57S/99mtPRpHk87zHZsYxuOfWsatbQv+W/8AwH+tA0Z91/x9zf77fzqKpbr/AI+5v99v51FQIWiiigAooooAKWkpRQAU+GJ5pFjjUs7HAFMAycCuq8M2ADBivztjJ64oA6rwHoKWh8xsPO4BLFensK9t8NaazRoxGAO+PauK8J2IDR5U9B/KvXdEtx5a4XgAdvagDf0qEKirjt1/CtlIgue1VLSPESjBB6fpVxB68CgCWOLJ6Yq15QAGetVvtCQhiTiopdUiWPKMD7jp1oAu7V3D1+lBVVHQDHtxWQuprng5J9O/NTw3XmcNn3HBoAtbA/3e3tUckI3KMHJ6fLx+J7VYiA4KYx6Z61d8tXQY4FAHO3Ft1AAzWZeaf8rH+ldVNAADjtWZPGzRkNgNzwKAPPNa0sybjgYIrz7xBpQjVwFyMHtXtd7b8MGXgjrXH+IdL3ROVXIwaAPnbxPoMNnaDV7wSGMFkjijCgyHoTuOduM8HBOa4G5t45YJLizWVYoiFdJCCU3E4+YY3dPQV9Ca3BYvbLaartVIXLxF1DRkEglXHXGR+teJ+KJtOtJb6z0iRpvPmLXDhNkS7WJCRjrgE9T6DFAHM0hpaQ0AJWtoX/Lf/gP9aya1tC/5b/8AAf60DRn3X/H3N/vt/Ooqluv+Pub/AH2/nUdAgooooAKKKKAClpKUUAWbGMPKCexGK9F8I2XmMvGeR/OuJ0WHzJFA9RXrfg61AAJ4AxigD0PwxYqpQhc4A6/SvS9JtQsSk9q5Lw7EoVAO4FdrFeRW8I3upx7j0oA102RQhnOAP8KwfEGuR2luzBhkA+nFZet+KFSNgrIFUf3u1eT+OfGaC1lWP5m2nByPSgDc1zx5l2Xz1PHGCv41BpPjFLiUxPOCCOFBHWvAtQ1qa4lLFgAMjj0pbDV5ku4gHCjcNx9s0AfU2ma3E0QCuSe4z1/GtBNZO9WMi7c4wDXienay9u8bCVTnnJPUnpW3FrzTqCrg7mxjPIoA9osPEOX2BskdOnStqz8SxCbyXcLnuxArxfT9TbztxcbjtUZI4FWb7UHnuk8ucdASR078fWgD3uKaK7TMbqwPHymop7YhWz9a47wVrMUUUaSOMdSc45wK9CLrLECpBB96AOde3QuQefrXPa5AI4y6YB5BxjFdHquYy2BisG7f7RG/94D60AeSeM7RJoZGRRvySRx69q+cvFlqLXWpwowH+fH1/wD1V9P+LoGjEjA4OeDXz58RYA1+JgQGxhh689vzoA4qkNKetIaAErW0L/lv/wAB/rWTWtoX/Lf/AID/AFoGjPuv+Pub/fb+dR1Jdf8AH3N/vt/Oo6BBRRRQAUUUUAFOXk02prdd0goA3PD6FJA3bIr2DwqUaJHDKqjGST0+teZaDbq4GeAMda1NV8Vpp5FrZglUzv5IBOelAHti+J7exTAljUdNzOOazrnxxHMrKsi7epO4V8+zeIbq4fc8jHHTLGki1GYv8rNz2zQB6prviZ5TsDqfcEelcXq1206OrSKWIIA+orMje5nYMRJgdTzTrhPlOSQwGcHORQBiSxlFJfscYFCPiTfxkc1NdvvyDjGMg+/pVFm/hB4oA6yy1B5YVkLqP4cE8CtrSdUdpBEG+XAUvkc89uK5PRLWS5Qrg/KdwX1xXW2enpbKsjABy3BOQRjvQB3Vjh/LAkDNt24B9B0NbFlaOWWW4O4LgYQ/kK5jRb6KCWKCNFbGFJJ7967O2vVZdsP3SMl+2fQUAXFvZUAG9VGeApzjivTfBGrvNp/lTuHdGw2D04FeOS3uDhlEe47dzcAcdcda73wLcN5rxrEyJjLSNnmgDvdVBbcUztHPXisAogY8k56V1ktxEbYgEMxXgE9TXKaxtt1Z4WALZOCTn8KAOf8AGOnRTWTFVAYgnPoc9DXy38Q4T58h/un+tfRusaqHtpotx8w/dya8C8exbnnOP85oA8xbknPWmGpJRh2HvUZoAStbQv8Alv8A8B/rWTWtoX/Lf/gP9aBoz7r/AI+5v99v51HUl1/x9zf77fzqOgQUUUUAFFFFABVqzHzCqoq/aAB1yePX0oA2pbs2dguGxI3QjqK56eQytuNTXc5lmIJyqnA+lQuqr0bn0oAjHBq9ZZB5zVReGGOa0LVQzrhtrH9aAOo0z/SLVlRyki9Cc88VTvjId56uOoxyav6dHOseEjAB53DJ7fpV2fSN+JHmwzAj5QeeB1oA4e6SSVtyoVCj0NNisJ3lUeWTnkDFeoWPhNJrKUSs3zAkMUIPTjvRb+GPsnynzG2qcNtJ5z0xQBn/AA90aWTUmZxmJY8bRk9xx7VrX2mXJ1ON5AfLRgQuOpz3rt/hvoWRdbsebwuDkHqK6268IAMWVGlKsCQM4HOf8/WgDzfSbNftLtMoXH3R79yBXTxFpLZUjiK9FUdwMdaddeHJLa48zz/mOFGV4yc8deBW9p1hbWdshupQSOAuO9AGOuk/J51yAz8Y3ZIPp25rZ0u4linkSNjuMZAAP60kTmePzZ/3AJ2oGByR649K0tJFpDJIxChgCMnv+NAGho+qSxuYrhmYknr1UGpfExMts00TFiASRnGapwy2/nu8JQMMeo/nW7qsNq+nzcbRtBDgkZJoA8R1W5naVxtbfuIznGOa5bxTol5eadJdoicjBTcckg84rstYgFtdSi4IEIbKv3YZrN1DWbOXSri3XcdhyrZ9/SgD54vkMdxIrDDAkEHjFVjWpr2G1O5dehkY/rWWaAErW0L/AJb/APAf61k1raF/y3/4D/WgaM+6/wCPub/fb+dR1Jdf8fc3++386ioELRRRQAUUUCgCSFctVu6xFCijG48nioIflGfbNMkYu5Y9zQA0Hmn4yOP5U0dDU0ZCLkjNAEYUnGB+laWlxjzAXxtA5BGarQTqsikoMDtWvZyRysGRAF7hwOf1oA6/QkhntDbyudrfd9uO1dFp2lu8iRLEV25ClkPB7cVR8DpatICq/KScsVzz9a9ottP37WihjJPB+UZ+tAGbouiwJbmOcqjj5wMfyrQ1iztLdNwRVfJAQJyfStiy8Mz3jAkrEVbn5c7gOlbWseG47eCKbaCCCrZHJyRjvQBw/g+QLeO92yxESZZVXgj3PevXtNudOksXYBQiYD/KepwR9eoryDWIxYSxQIhjSSQ7mC7uhHHHSvQ/DllPNpdt5YKQkZO4cnk9aAIdbsLa7cmBcyYBCqhA5759a4vULeG0j2/L527JLISF616lf+TptoHnKRFTxtA9/wCdeD+Nddmv9TjjQ7BkOMjpgn+lAE/iXXYLK1JimWW5ZfljjBJOR354/nXni+Ir2S+e4upnjCj/AFQBwOnv/wDXqLxPBHZx+e5KzHHAA+bj1rmUS4eaae5QQ26jAZ+Md8AZ5oA7C78aFS+3iRlIUIpAzgZxXUeHfGQlsd146pcRA/uQD0JGMf59a8O1XUwpkjtiGRujn7x/wFL4Nkkl1N4wCfMQjP40AeoeMdadmcAKLdiSpweRn1rz59TIuigP7tjg5rodfZ5LZDIuY3ZgV/utkZ965uy0pJ7sLMSqlscc96AOc1pCLmTjvWTXpHj3Qbazs/OgO2SFELf9NAx7+4z+Veb0AJWtoX/Lf/gP9aya1tC/5b/8B/rQNGfdf8fc3++386jqS6/4+5v99v51HQIKKKKACnxruP60yr9jDu5PegBRGFiJc4DcCqsu3OF6CrWqyDzFhXgR5B+veqNAC04ZNNFPXvQA6P71a2iwu8hTG446Dishcg8Vs6O/ltlsls9O3SgD0TwsZozGkcBWJsktxxgfrz/Kvd/BciwW5aZhtBwvQivnrQNRcDEbb3XgKCAAMfqfevS/DAiumVrm4KEHAUsB0x0oA960vUoJg3kI2F6Er1q14lha78PTxyboScFXjYbl5HTrXI6NcNawMsXmHIPJ56j0rTvfEb3GnrENqyoMN2GN2PXigDD0vSljuljeWSXIzulIJP1/Wu8s0dYYIoNptwBllwB9OK8ulubiTUCZmwoOCUPygZ6131hr9gmnx2zBxHjnkA/jzQBgeMEuL68KtvWBQMKuMnryf8K8u8U28MMB2RAEj/WMMnPp619Aq1lqNqxtQMheQwAPTpXmHjfQY4w6IJXkb5tzHhevAx2oA8X1u3DWEkylnY5KkqM9OleX6lKkbP8AKwlY857e1es6jaSWMux9zEEJnGMf0/8A11594p0Jo7ia5Ytlm6KAKAOPLs5Oa674awxP4mtTPLtCt91e57AnpiuVkQKTwcH2xTYbl4HVoWKspyCDyDQB9C+JBYJo9rvjTzGyrnCsQc8HNeSX+qTWl68aNjDHDAe9Okv728iZJjlZBvDM33mBHH5Yrmbt5C2JM5HHNAG9r+s3N9pKRTyF8qOoB6N6/hXHmtAybrUqf4TWdQAVraF/y3/4D/WsmtbQv+W//Af60DRn3X/H3P8A77fzqOpLr/j7m/32/nUdAgooooAdGNzAVuWUXlq7EZCKT9azbCLfKCe1dE1uVsWC9XOD9OtAHM3BLSMzHLEkmowtXbiE+YR9eaiEWDjrQBGqEj0qaKMMvJxVy3tJpFG1SFP8q19MtPLGcAAED5j1560Ac9HCxYYU4ra0+wkl5VwrDoCe2K1JbBZFGwjOM4JqOGNopAsPzN/sfMc9qAOg0fSL1FgIkhRT1yck/UCvQdF0O5a6JMpdlOSRXN+FdMv5Wt5C8UCJ65Zun0r3Dw9psEdm0mo3oG1d6heNx+lAF7TbZoV3TO3ToOew/wAKpeI7mEWF0LZRJtXkK3uDio7nVE3TNA5ggIMe4kZbgcdOPwrOsb+JzIzzqkfJ8tWGW7Y579elAGPY3F5cX8cIbZGzLu6E4J7nHSvUvD/h+GeCOSaROW5AYHJz2rzzQiZL6aVMRxI3yoe+Og/lXZaPq97PGohXYqsBgYOACeORxQB6PbWNvbRKkMaqAByO9Z+vQQrGs7x72QcD86hsL13jja6cRuDwvY4qtrerbrUsGRVHGAc546//AFqAPO/FtpDcq+AEYjITC+n0rxjxnbuLOYbljZBkhsdAPpXq3i3WRAGeKXc5YbgxBP3f/rV5p4nnTU7B2di5YEELj06UAeHXu+WRiXRuvK//AFqhtrQvMAzAc1pX6izu5olBKjsSCRx61DYpLJPuV0hbdjLrmgDvbvR7hvCkU8ZjZY1HLdVycfXHSuIuInlQsAN38RziveybK18KDbkyEJCC7gtgHcx6DNeGeIZFj1GYAhk3Eg56gmgC/pulW58Nahd3CKzR7Ao7Alsc1w9a0d9JbwTrCxVZOGAPBrKoAStbQv8Alv8A8B/rWTWtoX/Lf/gP9aBoz7r/AI+5/wDfb+dR1Jdf8fc3++386joEFOQZOBTR1qxapvkUUAb+g2JlKkrkZ6fhXYTadthwVOR149qqeE7LLLuIXBzzmuzuLYtCwKkMOKAPKtUt28xlQHAJyw/lT9IsN8iGQYHYEHnmtzULRmkLBTjceB9at6RZOZQ0ilEXkZyM89qANCw0qPyd8o2qenXJqC9iVVxBlj0GM4GPSt+KAXSqMHHAxnrWhHpUayrwdwxx0HFAHH2WlTON9zxEexY5P6Vs2trBaBYo0IEhGeevtntXS3eltOim3iOxQB3xTE0eOKJZL5skHpz+FAGVa6i5ZUjVosHIl37sD6Y45roH8UvLbSW8cjBhx5hLc8fSsSe3naQ+RGY4cEYGeaz5CIcQqh3Enc2fp/8AX96AN/TvEyQXLLeCW4Yg53Mf5V1Fk0V4YpxFsUn5UUHB5/XvXDQack86NbA7JTknHQcetd5pTWsNxDD5nnTjAEa5wpzwc0Ab1pp80Sx3Ekexe49Bura0++8uT93FKIWOfMIO0HsOn+c1VvLa4MKEykKwGEJIHByadLqCPE1tulSONBzyR/8AroA1P7VBDLNKo2gEEnGRiuXvtftpVkW2mUFR82WO0Z7/AF/Cua8X6x+4Vbc7QhwTu+Y/hXmkmtrBfMTI8kjDkBs4U9MDFAHc6lJF5LyeW0wAySsnU47A4zXJ3DQXl24G9IyPTAI6f54rA1HxnKqPGIiyoOMyEEfpWdaeI5bmRT5rqWO0KGNAHSat4as3hmnidC7KcupJJHv6V569gVvFihZiu45wCcAV6ZZag0tnJtUShchgDgHgdPWoLDSIbi6EiJhpDygbO0Z/OgCtrDSnTntllYny1KDJwOmf615ZqEbl2JB+U4zXsvjvTpNKW0uYiFilU/IM54PP04I/OvOb9opHYoYgW5AJNAHINwhHvUJrb1WyEFqsrIqPISVAPUA9axDQAla2hf8ALf8A4D/WsmtbQv8Alv8A8B/rQNGfdf8AH3N/vt/Oo6kuv+Pub/fb+dR0CFUZNa2kwbp068/4Vm243SAV0/h+Ddcx8fp7UAeg+GrLaq4Bz/8AWrrltsRlSTyDj2xiqfh6ABFwOfSurMANq4xxjNAHmU9iTduvO0Mea0EtBgZ6duDV3VIvLn+UZznPFTadFudQTux3x70AP0uNwuQhABAY4OK1obVpphgNnjk/Wr+n2wk3RbRn1q8unN9qjWP5uecDgc0AaljpscUAEhLMAD+NYmqvBv2FDI2cbF7cfrXUYkjRY8DA4JAxkVm6npgaBj5ezJzvCjP4e1AHFauZIwgB7DcqA9PTOaxr6GKIHcCJ2Hyrg+3OO31ra1Pf537pS6rwGCnrjnHvUcGlSWmbq6wGbJTeCcn+v0oAxmnnCsYwSP4VTP8An1rtfAptBfbbxtsoGAe5OR+VcxNeIvmxxMDK6kYVcYJHoP51Z8PQpDqCzO5UxAfNjgnNAHsniNoxZQpHneFyB3Izjr6VwGu6k8KuEIWRSNi+uDjmuuv50n0aGWQlmYHaQPQgV4l481SWPXY4QnyLGpxgggZP5DFAGV4l1+WW5kRlCJ0YpkBfQk1yWoWi7IrlXkV5EBLrk4z9P5e9bviS1tysYSSKMsOSF6HH61wsjyQnyo2I2HHuDQBBfTrsYKd5z94k9MVUgu3jlUjtxUcxdiQwz9ajjj3SAMSvOM4zQB3XhrU3LeSRuLZx1AGf/wBVen+FNMnuZ0nZPKbJyEOSOmfrXknhi1kLNKzgc4xtzxxXsuiarDaWPlcxYAP3Tzz/AProAp/Ge/guNMMbEiaF2IQAjgsvT8s14Lc3OHIV6734j3hur24kByrMW3AcEH+VeZS/6w9+aALN9dNLDHGTwgOPx5qgae5yaZQAla2hf8t/+A/1rJrW0L/lv/wH+tA0Z91/x9zf77fzqOpLr/j7m/32/nUdAi3YLlyfSu48MQZlU4HH+FcTpv3z+Fei+FEHlqT3/wAKAPSdJASNfX0rqIcyQuBgHHBxmuZszwpHQeldPYsNpx0oA5m9tmMoUgZzyQMD8Bmnwp9lcPgbB3/GtfUbUv8AMo5Pas+W0OVMnboeMUAXrG/xJ5SrjJHzHgnmu00fZHJlVWQ4zzXnikIS5YADnnqa6DwvcT3NyBEDjq2e1AHb6opljjW3iXhADgVivbXl2EtkUlEbcWx1OOmM9K7WGzWCxj2KDKQCSQD2/wD11Y0O18q8PmRguxBIIAxxQBwn/CKMlv5867Ap6YySaw9etzPKqAlVVCdoXOOPrXsPipIfsLtg7xg8d/avGfEuoCGW5MACBo2XgdOPzoA4/UZbWG5lVYlEgUgKB7YJPPNc03iWOHUVtIHEwZwrHHTtjOeMVa1OCSW1luF67SVY4xux3/WvOoOL3e75keTgKRz83p6cUAeyXl0bvToEh+5E52rnnnrn8hWN4nsFnhi1CZQHAChdvzYz0p/haKVrNGjm8xt3zZxgncBiun1SySG23Tgt5yE7SQT1I4/KgDxvVYpNTm8x8xeV1jxk45wevrXOX0IijSR2Jkbr7iu48Rzwi3uUYggoNy7f615tcys+BGG2LwAxzigCKeQO5O3BHFRo+xv6U1n9Rg1ExoA6Xw5qXk3IBJPOOQMY4969dlC3Xgu4up48AQtLHwDyvbr35rwWwt3uZwifnXqGpXjaR4aTTmkJCwSbjxjc3QD8WoA4bU9SW84y2V7N0rFlTkkdqST7x+tKCPJfPXIAoAgNIaU9aQ0AJWtoX/Lf/gP9aya1tC/5b/8AAf60DRn3X/H3N/vt/Oo6kuv+Pub/AH2/nUdAi3p5xIR616B4dlCxRj29K86t22ODXYaTeiONADk8AAUAerWV0oiByMV02jzNLgnp/wDqrz3S5GdgXI+g7V6FoR2gfzoA33iDHPYCsu7t2J+XBPPFdJbwCUc85FXbTRI5ZAc5A96AOMs9IedhlS2TgADrz3r0/wAE+HFtQXkiUDIO3Ax1NWtH05AVSDGzjJ9ea7SCIIgHpQBD9kQAYAz16daijs/JbeOWz2rQpaAOQ1398ZFmUgAYA9DjivGfH3hu7n0+8dVcPsOCMHIOM4r6PuLeOdSsig5BFUrvSYZ4Gi5CbSuOOM0AfCeri8sbN4HlAJBVlQ9Qev6Vgh4LZcF91wD1yAF59a9u+OvhCXS9WM1gM2jfO4yMrwDzx0zmvnvUJHF3Kfl5Yn170Aeo+CdVtbK1dJJYxIwyXz1ORgA/56fWtXxJ4lhNxaDzl8sx4kwADnP6V49aXk3mjYfmxj6c1fneVvMkaeJ42w0kW8At82Rjjk0AWNRcCR0MgkIbevQ5Uk9a5e8GJOmCea1JL1JXVkysmcAE+1UZYvMdRg57YoAzWNJjNTzQ+XnrTUAeTHA59aANLQ2WOZS4PDAnjPFa/ii9S8u2K52YypJ65ArQ0fTIZPDtzJNujk525PoKy5rLz4irnaUBK89fagDmnAzxUTHjFWLldjEHsarE80AJSGlpDQAla2hf8t/+A/1rJrW0L/lv/wAB/rQNGfdf8fc3++386jqS6/4+5v8Afb+dR0CHp1FdFopwVORXOL1rd0yQAqM0AelaFKZCoY5r03Rl+TAwK8w8NAIQ7HH416RpVwBjyxuJH0FAHdabKqqDIRj1zW/YuJnVYxhT1461zOlwmUqznPFd7oMCptIGDj+tAG1o9t5UeePpWp0FMh4UCpDQAlFFFABRRRQBy3jfw5HrdjcBwG3RFDxz0r5F+JPw1m0u7kl06RTFklkY9OR0496+465Txf4NtNctH8hViuTzkk7Wyec46fhQB+fvlz2Uw3/I6dMjNLqRkF2sjOC0gDZFfSfi74WSQCWSawwuNnmKSy/XNeM+J/Bt3Y+bc2oaRIyD5QUlsZ7evagDz52Jk3HBPqKvW00ok2BldW52sQcnFRNauGIIxg8g5BFdDomgXFxfxMsfyKVYnqCPSgDBkjN4m8rsxwctnJrS0bQwZo5bgjbv2hc8njJru9R0ZonHloqRdiM+nI/P1qjfQi0ktllADRksdue//wBYUAUbu7NrZToAFjAdAv8As8KB/OuZ/tVhE0RUYHQ5q/4wv/PumUcL97APHQYFc0pDOo6etAEN3IXmZj35qvUk7bnJHTtUdABSGlpDQAla2hf8t/8AgP8AWsmtbQv+W/8AwH+tA0Z91/x9zf77fzqMVJdf8fc3++386joEKKu2GTKACapDtWjpgzKMUAek+F4cKoPJzzk16locY4FeZ+Gm5XHWvUdE6cHHFAHeaIoJUH09a7vSSBt46159pUu3ae3Su10qckLtOf60AdZERtqXtVW0bKCrQPFACUUZGfeigAooooAKKKKAEdFkRkdQynqD0NcF4q8A2l8sklnGsLsckKT19RXfUvagD5e1z4MR3F+szwOu7BZl3AEA/wA6F0a30u4jtVhOyOMANglcAY/pX0pqECyQMpHX2rjL7w9FKMKmCDnOKAPJpfDst2I943QsQQRxXmHj+3lg1W6zgRqwUD6L0r6O1Gxe1090QgkZ24HoK8J8cWhnvZpJdwYgZPrxQB41eRyCV8gkHnPNUzhAzEdiBXU6siRhkQfU1yl7IC5VegoAqseaSg0UAFIaWkNACVraF/y3/wCA/wBaya1tC/5b/wDAf60DRn3X/H3N/vt/OoxUl1/x9zf77fzqOgQorQ0sgSis8VZs32uKAPVPDci/LjFelaPKMDAryHw1PkqO/wD9avUNDkyAAKAPRNMYHH0x0rtdIbpjGMelcBpcmFHSuz0mTlenSgDtbWULFk849qtrMpQk1zRvBEoxinpd+ZkevFAHQideOeTUysCOtc5atKW+YYHrmr6NIFEh+6O1AGsaSoYJhImentU3WgAooxS0AIKU0majmkCKSaACRh0NY+pN8jFSDjnGKdNegyhXAAPfNZer3aR2jr95iQBkf59KAOZ1m/iWCQSttIHQjODj1rxDxtOsssrqBjoMD2ruvFNy4V0zgZySBivJfF16IoX6HnH6GgDg/EdwEJVSM/TrxXKOckn1q/qtwZpiTWcaAEooooAKQ0tIaAErW0L/AJb/APAf61k1raF/y3/4D/WgaM+6/wCPub/fb+dR1Jdf8fc3++386joEFSxHDCoqcDQB1mgXWyRRmvVvDtznqe1eJabMVdea9M8NXfy9e3+FAHsWmXGVGD2rrNOuSCprzjSLjKryMYrr9On4AzQB1Ms5yDk/lTrC4YzgkZA7VkmdWi2k4OOKW3mdCD1HegDtVvkJXpwPxNW47jdCBn5c/wBK4gMTKGL4HXFdDZeY1sp7nnmgDQWZvM8uMnBratZCy88+9YtuoRcuBn2rStpUGSOvvQBpEjmms+KrGcDPSoJLjjigC47gVnXkrMWA6jimSXIAwT1qjPeDJxljQBHMwV1xyfcVgeIXP2ZyOo5q7qt6kABkYDjpxXCeJvEirblIyCT15oA5DxJekCRc56/yrxrxjeF5nXPT/Cu88R6ivlSyEjLcKPwryTXZy8sjE9aAMSdtzk1DTmptABRRRQAUhpaQ0AJWtoX/AC3/AOA/1rJrW0L/AJb/APAf60DRn3X/AB9zf77fzqOpLr/j7m/32/nUdAgpRSUooAuWjYYV3Phu5IPWuBtzhhXV6DJtkoA9e0a5+Ref1rrrC6PA4xgd+a840m4+UdMYrqrO64XmgDs47jK5BH41csZw/wAp6j3rmra4BUAkVpWcwVs7uvXmgDqFUSSJkjCj1rdguQFVQR0wOfauVtrngcitCC645IoA6cXI2Yzn8amjuyO361zsV2f7w/OrK3WepyaANz7WMnnn61FJdcHBH1zWS0+c4NQTTlQSG5FAFm7viDjcOKppqHBUnkdDWfPMXc5NVJJQjE5oAp+JtR38scfL/jXnOsTq2TuwO/Ndb4jIa33jHHbNea63csqnJA9s0Acl4nvmYuSenA/KuA1CYySHJrodfuSzMMjrXKznLmgCM0lFFABRRRQAUhpaQ0AJWtoX/Lf/AID/AFrJrW0L/lv/AMB/rQNGfdf8fc3++386jqS6/wCPub/fb+dR0CCgUU5VJOBQBLB98V0mjkiQY9KyLGzd2BxXW6TY7WAKn8jQB0umSEIvbit+zvAXAB4HvWLZxAIuOhFa1rFGhBBwaAOgtbgnoTzWrbzng/1rnrdlUY3VpW0yjoRQB09tc4jyT0qew1NblHZA4CuUG4EE4HPX34/CsO3uFwAG6+9GjuY7OJjI7F13kP1BPP8AWgDroLnJPX/Gri3HOa56Cdf7wq6twuPvfrQBrtcZz/jUbz4BJ7+9ZxuF9ajluh0BoAtyT5PFZt/OsQYk/hSNdLjtn61k6nOG3YPUetAGFr2ptIAEJAHPWvPddnLKTk812GpoGBGcVxmtWzfwmgDz7VnLSNWIxyTW5q0Eis2RWG4wcGgBKKKKACiiigApKWkoAStbQv8Alv8A8B/rWTWtoX/Lf/gP9aBo1aKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral chest radiograph of a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) demonstrating prominent consolidative opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25281=[""].join("\n");
var outline_f24_44_25281=null;
var title_f24_44_25282="Iliopsoas anatomy";
var content_f24_44_25282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Iliopsoas anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The psoas muscle arises from the transverse processes of the lumbar spine, while the iliac muscle arises from the inner surface of the ilium. Both insert along the medial aspect of the proximal femur, primarily at the lesser trochanter, and act as the primary flexors of the hip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Novachek TF. Adductor and Iliopsoas Release. In: Operative Techniques in Orthopedic Surgery, Wiesel SW (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25282=[""].join("\n");
var outline_f24_44_25282=null;
var title_f24_44_25283="Aflibercept (ophthalmic): Patient drug information";
var content_f24_44_25283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aflibercept (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/18/27939?source=see_link\">",
"     see \"Aflibercept (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14933691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eylea&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14933952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular degeneration.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2835759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14933951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3568964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aflibercept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14933955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14933956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3568982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14933957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14933954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14933958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86381 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25283=[""].join("\n");
var outline_f24_44_25283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933691\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933952\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933951\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933955\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933956\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933957\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933954\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933958\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/18/27939?source=related_link\">",
"      Aflibercept (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/18/2342?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37524?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25284="Correction penile curvature";
var content_f24_44_25284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal plication for correction of penile curvature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25284=[""].join("\n");
var outline_f24_44_25284=null;
var title_f24_44_25285="Chlorpheniramine, pseudoephedrine, and codeine: Drug information";
var content_f24_44_25285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine, pseudoephedrine, and codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/49/789?source=see_link\">",
"    see \"Chlorpheniramine, pseudoephedrine, and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10964105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phenylhistine DH [OTC];",
"     </li>",
"     <li>",
"      Tricode&reg; AR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Products listed in dosage forms may contain differing amounts of active ingredients; however, the dosing volume and frequency are the same.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cough, rhinitis and nasal congestion:",
"     </b>",
"     Oral: 10 mL every 4 hours (maximum: 40 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Products listed in dosage forms may contain differing amounts of active ingredients; however, the dosing volume and frequency are the same.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cough, rhinitis and nasal congestion:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: 5 mL every 4 hours (maximum: 20 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylhistine DH: Chlorpheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and codeine phosphate 10 mg per 5 mL (120 mL, 480 mL) [contains ethanol 5.3%, menthol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricode&reg; AR: Chlorpheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and codeine phosphate 8 mg per 5 mL (473 mL) [dye free, ethanol free, gluten free, sugar free; contains propylene glycol; berry vanilla flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F150416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of cough associated with minor throat or bronchial irritation or nasal congestion due to common cold, allergic rhinitis, or sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tricode AR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2-8 mg/5 mL (473 mL): $96.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zodryl DAC 25 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-0.333-1 mg/mL (118 mL): $35.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zodryl DAC 30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.286-0.286-1 mg/mL (118 mL): $35.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zodryl DAC 35 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75-0.25-1 mg/mL (118 mL): $35.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zodryl DAC 40 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.333-0.222-1 mg/mL (118 mL): $35.00",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8707 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25285=[""].join("\n");
var outline_f24_44_25285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854548\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10964105\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150414\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150406\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150410\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150407\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150397\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150387\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150416\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150398\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199152\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150412\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150411\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150402\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323064\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150400\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8707\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8707|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/49/789?source=related_link\">",
"      Chlorpheniramine, pseudoephedrine, and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25286="Organization and elements of a home hemodialysis program";
var content_f24_44_25286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Organization and elements of a home hemodialysis program",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Connie Anderson, BSN, RN, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Christopher R Blagg, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25286/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/44/25286/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A treatment program for all patients with end-stage renal disease should provide the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The best possible patient outcomes",
"     </li>",
"     <li>",
"      The maximum medical, social, economic, and psychological rehabilitation",
"     </li>",
"     <li>",
"      Few ill effects",
"     </li>",
"     <li>",
"      The highest possible quality of life",
"     </li>",
"     <li>",
"      Excellent patient compliance",
"     </li>",
"     <li>",
"      Maximum opportunity for employment, reemployment, or education",
"     </li>",
"     <li>",
"      Maintenance or \"repair\" of family dynamics",
"     </li>",
"     <li>",
"      The least possible stress on patients, families, and the health care team",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among conventional dialysis modalities, home hemodialysis three times a week during the day or overnight most readily achieves these goals. In general, patients treated with home hemodialysis lead more independent lives, have better rehabilitation, and have higher survival outcomes than those treated with other dialysis modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. This is due in part to home hemodialysis patients generally getting more adequate dialysis than those treated in center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .) Additional benefits include the assumption of more individual responsibility for performing the treatment and a diminished role for dialysis in the patient's life (rather than being dominated by a dialysis schedule).",
"   </p>",
"   <p>",
"    Most importantly, home hemodialysis provides the best opportunity to perform more frequent dialysis, either during the day or overnight. This results in further striking improvement in patient well being, reduces symptoms during and between dialyses, and improves quality of life and opportunity for rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .) Unfortunately, Medicare currently only pays for three dialyses weekly unless medical justification is provided, although every report in the literature has confirmed the benefits of dialysis performed five, six, or seven times a week.",
"   </p>",
"   <p>",
"    Conventional home hemodialysis using currently available equipment three times a week usually requires the presence of a partner (family member or assistant, paid or unpaid) to help the patient. Unlike",
"    <span class=\"nowrap\">",
"     CAPD/CCPD,",
"    </span>",
"    which can be performed without assistance, a home hemodialysis partner shares some of the stress of technical and medical problems and has to be trained to treat potential emergencies. Patient-friendly equipment designed specifically for home use that allows for more frequent hemodialysis and, in some cases, does not require use of a water treatment system means there is less need for a partner to take as much of an active role, so some patients can complete the whole procedure themselves.",
"   </p>",
"   <p>",
"    The elements required to organize a successful home hemodialysis program are discussed in this topic review and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELEMENTS OF A HOME HEMODIALYSIS PROGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of almost universal Medicare coverage for the treatment of end-stage renal disease, the financial concerns of patients and dialysis programs were a major driving force behind the development and popularity of home hemodialysis. To allow charitable funds, endowments, and other limited funding resources to be used to treat the greatest number of patients, the policy in Seattle and some other programs required as many patients as possible to use home hemodialysis, since this was less expensive than outpatient dialysis.",
"   </p>",
"   <p>",
"    As a result, some 40 percent of the 10,000 dialysis patients in the United States were on home hemodialysis when the Medicare End-Stage Renal Disease (ESRD) program began in 1973. However, the proportion of patients with renal failure choosing home hemodialysis in the United States has subsequently steadily declined and has diminished even more rapidly since 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/10\">",
"     10",
"    </a>",
"    ]. By 2002, only 1758 patients (0.57 percent of all dialysis patients) were on home hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/11\">",
"     11",
"    </a>",
"    ]. The factors responsible for this decrease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, over the last few years, the use of home hemodialysis in the United States has begun to increase due to growing interest in more frequent hemodialysis and the development of more patient-friendly equipment. By 2007, the patient numbers had increased to 2999 (0.81 percent of all dialysis patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/9,11\">",
"     9,11",
"    </a>",
"    ], and at the end of 2010, to more than 4000 home hemodialysis patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A successful home hemodialysis program starts with support from the patient's nephrologist. He or she must educate the patient about the benefits of home hemodialysis and encourage them to select this treatment option. This process begins with CKD modality education, which may provide the patient&rsquo;s first exposure to the possibility of home hemodialysis. The 2008 Medicare conditions for coverage require that patients be educated about home modalities and that exclusion criteria to home modalities be identified yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There must also be a strong infrastructure in place to assure patient support in the home and to foster patient independence and self-motivation. Unfortunately, most nephrologists in the United States today have had little or no exposure to home hemodialysis during or after their training because of the current lack of home hemodialysis programs.",
"   </p>",
"   <p>",
"    Successful training leads to a confident, competent, and independent patient and helper. This goal requires a multidisciplinary approach coordinated by a home training nurse who works with the nephrologist, social worker, dietitian, and equipment technician. Follow-up home support, available 24 hours per day, provides the framework that sustains day-to-day operations in the patient's home and allows for monthly multidisciplinary reviews and interventions when problems arise.",
"   </p>",
"   <p>",
"    With increasing use of overnight home hemodialysis, remote online monitoring of patients is used in some programs to ensure safety, accurate data collection and reassurance of patients, staff and others [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/13\">",
"     13",
"    </a>",
"    ]. Nevertheless, other nephrologists with home hemodialysis experience remain unconvinced of the benefits of this expensive process in terms of patient safety. A review from the program in London, Ontario, suggests that nocturnal home hemodialysis patients should be monitored for the first three months at home until the patient is stable and compliant, but is only necessary thereafter if indicated by medical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .) In the future, it seems likely that use of the internet for communication and transmission of information will become important [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A successful home hemodialysis program must become financially sound and self-supporting. However, because Medicare payment for training dialysis is inadequate, it currently takes 15 to 25 home hemodialysis patients to reach this stage. This requires a program that supports at least some 20 patients. This is also important in order for the nurses providing the training to maintain their skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Objectives of the home hemodialysis training program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of training is to assist patients and their helpers (if necessary) to perform dialysis safely, with good quality outcomes and without undue anxiety. Additional important objectives are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify suitable candidates for home hemodialysis before they have to start dialysis",
"     </li>",
"     <li>",
"      Train the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      helper (if needed) to perform safe hemodialysis in the home",
"     </li>",
"     <li>",
"      Instill confidence in the patient that support is always available to provide medical or technical assistance when problems or emergencies arise",
"     </li>",
"     <li>",
"      Provide emotional support as patients, families, and helpers adjust to the stresses of home hemodialysis",
"     </li>",
"     <li>",
"      Assure staff that patient and helpers possess expertise in all necessary aspects of the dialysis procedure (venipuncture, water treatment, initiation and termination of the dialysis procedure, vital signs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      administration, saline administration, emergency procedures, etc.)",
"     </li>",
"     <li>",
"      Provide monitoring and follow-up care once the patient is home, so as to assure successful adaptation to the home environment",
"     </li>",
"     <li>",
"      Provide continuing education and updating of procedures",
"     </li>",
"     <li>",
"      Detail the specific roles of each health care team member, including nephrologists, training nurses, technicians, dietitians, and social workers",
"     </li>",
"     <li>",
"      Ensure that the home hemodialysis patients have outcomes at least as good or better than the outcomes of patients dialyzing as outpatients in dialysis units",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Identification of home hemodialysis candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the start of the ESRD program, Medicare regulations have required that all modalities of treatment, including home hemodialysis, be explained and offered to new patients. This rarely happens. One survey in 2002 showed that presentation of treatment options was delayed for at least one month after the first dialysis for 48 percent of patients and only 12 percent of patients were presented with the option of home hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/6\">",
"     6",
"    </a>",
"    ]. In the past, there were few home hemodialysis training programs and, as a result, home hemodialysis was not entertained as a possible modality at most of the more than 4000 dialysis facilities in the United States.",
"   </p>",
"   <p>",
"    For those facilities that do offer home dialysis, the burden of finding candidates and a training program they can be referred to rests primarily on the nephrologist or on the nurses and social workers in the facility. Improved",
"    <span class=\"nowrap\">",
"     pre-ESRD/CKD",
"    </span>",
"    education that discusses all treatment modalities hopefully will lead to access to home hemodialysis for all medically suitable patients.",
"   </p>",
"   <p>",
"    A potentially important new stimulus to home hemodialysis is in the new ESRD Conditions of Coverage that became effective on October 14, 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/16\">",
"     16",
"    </a>",
"    ]. These \"require evaluation of the patient's abilities, interests, preferences, and goals, including the level of participation in the dialysis care process; the preferred modality (hemodialysis or peritoneal dialysis), and setting, (for example, home dialysis), and the patient's expectations for care outcomes.\" One proposed regulation is that \"Patient records must demonstrate that each patient was informed about all dialysis modalities and locations for home dialysis training if that service is not available at this facility. If the patient expressed interest in home dialysis and was determined to be a suitable candidate, the plan of care should list this modality as a goal and identify ways to achieve it (eg, timeline for training in home dialysis at current facility, referral to a facility certified for home training and support).\"",
"   </p>",
"   <p>",
"    Some patients will request home hemodialysis spontaneously; more frequently, however, physicians, social workers or nurses in an outpatient dialysis center refer the patient to a home hemodialysis training program. If done early, this referral gives the patient opportunity to meet and be evaluated by training staff and to meet successful home hemodialysis patients. The patient's and potential partner's ability to learn necessary skills and concepts are also assessed by the staff. In addition, these meetings help the patient understand the advantages of home hemodialysis, including the value of independence, a more flexible dialysis schedule, and freedom from the nuisances of travel and other inconveniences associated with outpatient hemodialysis.",
"   </p>",
"   <p>",
"    Factors involved in patient selection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Living circumstances and accommodations",
"     </li>",
"     <li>",
"      Learning ability and motivation",
"     </li>",
"     <li>",
"      Level of patient and family anxiety",
"     </li>",
"     <li>",
"      Type and severity of medical conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Motivation and compliance are most important, but the degree of anxiety of both patient and family must not be neglected. The social worker plays an important role in assessing the patient's social, emotional, and financial support for home treatment.",
"   </p>",
"   <p>",
"    The major contraindication to home hemodialysis is frequent instability during dialysis due to severe cardiovascular disease. Age and diabetes themselves are not contraindications. A useful tool to help assess a patient's suitability for home hemodialysis or peritoneal dialysis has now been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To alleviate patients' natural anxieties, it is useful to point out that if they can drive an automobile, they can certainly learn to \"drive\" a kidney machine. In neither case do they need a detailed understanding of what is inside the machine; rather, they must learn how to operate it safely and understand how to deal with the problems that may occur. In both cases, technical and other support is available as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Specific requirements for home hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful home hemodialysis requires the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood access that is easy to use.",
"     </li>",
"     <li>",
"      Dialyzer, duration of treatment, and ultrafiltration rate chosen to ensure adequate dialysis while minimizing symptoms. The patient must fully comprehend these elements.",
"     </li>",
"     <li>",
"      Cautious use (if any) of antihypertensive drugs and regular monitoring by the nephrologist.",
"     </li>",
"     <li>",
"      Equipment, including water treatment, chosen for reliability, adequacy of monitoring, ease of use, and ready availability of maintenance and repair services [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accommodations with suitable sources of electricity and water, if applicable. New technologies may not require alterations in electricity and plumbing. Water treatment in the home will be based on analysis of the local water supply. A home visit by the staff assists the patient in determining the need for any electrical, plumbing, or other modifications to his or her living arrangements [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/19\">",
"       19",
"      </a>",
"      ]. The American Association for Medical Instrumentation has published detailed standards for water quality, water supply, drain and power, the environment, equipment, concentrate, and monitoring for home hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Development of a comprehensive assessment and plan of care that can be used to set goals and targets for the patient to achieve while at home. The plan of care for home patients must meet the same standards as those provided for the in-center patients.",
"     </li>",
"     <li>",
"      Ability to manage and monitor drug administration to assure compliance with the use of erythropoietin stimulating agents, vitamin D and iron, if applicable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiation of dialysis therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To separate the potential patient from patients on outpatient dialysis at the facility, some programs start maintenance dialysis in the home training unit, which, if possible, should be separate from the main treatment area. Others begin training soon after a patient has been stabilized on dialysis. An early start in or transfer to the home training unit encourages independence and confidence from the beginning. The training staff should be selected for their teaching skills as well as their knowledge of dialysis.",
"   </p>",
"   <p>",
"    The education schedule can proceed in a variety of ways to accommodate the patient's work and social schedule. Once the patient is medically stable and has a suitable blood access, he or she should be taught to insert his or her own needles. This is often the most difficult hurdle for the patient to overcome. Many programs currently teach patients the buttonhole technique for cannulation of the access [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25286/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Most programs train and educate one-on-one during actual dialysis treatments. At the same time, teaching can also begin about such subjects as aseptic technique, the meaning of vital signs, the importance of vascular access care, diet, medications, and renal disease and its complications.",
"   </p>",
"   <p>",
"    After gaining competence in blood access, subsequent training addresses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Setting up the equipment including water treatment equipment",
"     </li>",
"     <li>",
"      Initiation and termination of dialysis",
"     </li>",
"     <li>",
"      Preventive maintenance",
"     </li>",
"     <li>",
"      Handling of emergencies",
"     </li>",
"     <li>",
"      Administering medications",
"     </li>",
"     <li>",
"      Documentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient also develops expertise in routine dialysis procedures: monitoring of vital signs during dialysis, prescribing ultrafiltration, completion of flow sheets, full documentation of any event, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and saline administration. The patient and helper are taught how to record and complete dialysis log sheets and how to take and mail blood samples for laboratory tests. Training must also cover equipment maintenance, ordering and storage of supplies, and how to access the support services. The patient or family member can administer erythropoietin-stimulating agents at home and other medications if the patient's insurance will pay for this. Parenteral iron is probably best administered at the dialysis facility, which also gives a good opportunity to assess the adequacy of dialysis.",
"   </p>",
"   <p>",
"    The overall goal of the training program is to give individualized instruction to the patient and helper so they can dialyze safely at home. As far as possible, the patient should be in charge of and responsible for the treatments while the partner serves as the assistant, although this may vary depending upon the abilities of the patient.",
"   </p>",
"   <p>",
"    Generally, home hemodialysis training takes between three weeks and two to three months, depending upon the program and the skills and learning abilities of the patient and partner. During training, progress must be assessed and recorded at regular intervals to ensure acquisition of the necessary skills and knowledge. A mechanism for objective scoring of the patient's skills is important in order to ensure patient consistency in carrying out procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predischarge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to move out of the training center and into the home is a mutual one between the patient and training nurse. To ensure the competence of the patient and helper, the last few dialyses can be done alone behind closed doors, with staff available by phone as would be the case at home. Alternatively, a training nurse can attend the first few sessions at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ongoing support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and partner must know how to react in emergency situations. They must also be aware that a staff member is available by telephone 24 hours a day to answer questions, assist with complications, or refer to a clinician or technician if necessary. Home visits by training staff are essential; the first should be shortly after the patient goes home and subsequent visits should be at 6- or 12-month intervals, or as required. These visits allow the training nurse to observe dialysis technique and safety, provide information and education, observe family dynamics, and answer questions. This also is an opportunity to remind the patient to make appointments to see his or her nephrologist in the office or to be seen in the home dialysis clinic by the training staff.",
"   </p>",
"   <p>",
"    Routine blood samples must be sent to the laboratory monthly, and the clinician and training staff review the results and the dialysis log sheets. Nephrologists follow home hemodialysis patients in their office, usually once a month or more frequently, as medically required.",
"   </p>",
"   <p>",
"    In the United States, Congress has passed a new prospective payment system for the ESRD program that became effective on January 1, 2010. There may be more opportunities to increase home dialysis as a therapy within the PPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12850220\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A successful home hemodialysis program requires a multidisciplinary approach that includes a nephrologist, home training nurse, social worker, dietitian, and equipment technician. The nephrologist should educate the patient about the benefits of home hemodialysis. This process begins with CKD modality education, which may provide the patient&rsquo;s first exposure to the possibility of home hemodialysis. The 2008 Medicare conditions for coverage require that patients be educated about home modalities and that exclusion criteria to home modalities be identified yearly. Follow-up home support that is available 24 hours per day sustains day-to-day operations and allows for monthly multidisciplinary reviews and interventions. Remote online monitoring of patients is used in some programs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Elements of a home hemodialysis program'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The objectives of training for home hemodialysis are to identify and train suitable candidates, to instill patient confidence that support is available to provide medical or technical assistance, to provide emotional support, to assure staff that patient and helpers possess expertise in all necessary aspects of the dialysis procedure, and to provide monitoring, follow-up care, continuing education and updating of procedures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Objectives of the home hemodialysis training program'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of home hemodialysis candidates relies primarily on the nephrologist or on the nurses and social workers in outpatient hemodialysis facilities. Factors involved in patient selection include living circumstances and accommodations, learning ability and motivation, level of patient and family anxiety, and type and severity of medical conditions. The social worker plays an important role in assessing the patient's social, emotional, and financial support for home treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Identification of home hemodialysis candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful home hemodialysis requires easy-to-use blood access, a dialyzer prescription that ensures adequate dialysis while minimizing symptoms, cautious use of antihypertensive drugs, reliable and easy-to-use equipment, ready availability of maintenance and repair services, accommodations with suitable sources of electricity and water, a plan of care that sets goals and targets, and a means to manage and monitor drug administration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Specific requirements for home hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generally, home hemodialysis training takes between three weeks and two to three months. Training includes needle insertion, aseptic technique, the meaning of vital signs, vascular access care, diet, medications, and renal disease and its complications. Subsequent training addresses setting up the equipment, initiation and termination of dialysis, preventive maintenance, handling of emergencies, administering medications, and documentation. Training must also cover equipment maintenance, ordering and storage of supplies, and how to access the support services. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initiation of dialysis therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient and partner must know how to react in emergency situations and be aware that a staff member is available by telephone 24 hours a day to answer questions, assist with complications, or refer to a clinician or technician if necessary. Home visits by training staff are essential. Monthly blood samples must be sent to the laboratory and reviewed by the clinician and training staff. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ongoing support'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/1\">",
"      Woods JD, Port FK, Stannard D, et al. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996; 49:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/2\">",
"      Covic A, Goldsmith DJ, Venning MC, Ackrill P. Long-hours home haemodialysis--the best renal replacement therapy method? QJM 1999; 92:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/3\">",
"      McGregor DO, Buttimore AL, Lynn KL. Home hemodialysis: excellent survival at less cost, but still underutilized. Kidney Int 2000; 57:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/4\">",
"      Saner E, Nitsch D, Descoeudres C, et al. Outcome of home haemodialysis patients: a case-cohort study. Nephrol Dial Transplant 2005; 20:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/5\">",
"      Blagg CR. Home haemodialysis: 'home, home, sweet, sweet home!'. Nephrology (Carlton) 2005; 10:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/6\">",
"      Mehrotra R, Marsh D, Vonesh E, et al. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney Int 2005; 68:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/7\">",
"      Pauly RP. Nocturnal home hemodialysis and short daily hemodialysis compared with kidney transplantation: emerging data in a new era. Adv Chronic Kidney Dis 2009; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/8\">",
"      Diaz-Buxo JA, Crawford-Bonadio TL, St Pierre D, Ingram KM. Establishing a successful home dialysis program. Blood Purif 2006; 24:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/9\">",
"      Moran J, Kraus M. Starting a home hemodialysis program. Semin Dial 2007; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/10\">",
"      Blagg, CR. What went wrong with home hemodialysis in the United States and what can be done now? Hemodial Int 2000; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Vol. 3, Bethesda, MD. p.510, Table D1.",
"    </li>",
"    <li>",
"     file://www.cms.gov/Regulations-and-Guidance/Legislation/CFCsAndCoPs/ESRD.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/13\">",
"      Schlaeper C, Diaz-Buxo JA. Home hemodialysis and remote monitoring: current technology, requirements and capabilities. Blood Purif 2005; 23:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/14\">",
"      Heidenheim AP, Leitch R, Kortas C, et al. Patient monitoring in the London Daily/Nocturnal Hemodialysis Study. Am J Kidney Dis 2003; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/15\">",
"      Seto E, Cafazzo JA, Rizo C, et al. Internet use by end-stage renal disease patients. Hemodial Int 2007; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/16\">",
"      42 CFR Parts 405, 410, 413, et al. Medicare and Medicaid programs; Conditions for coverage for end-stage renal disease facilities; final rule. Federal Register 2008; 73:20370.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.homedialysis.org/files/pdf/pros/MatchD2007.pdf (Accessed on September 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/18\">",
"      Morgan D, Schlaeper C, Lockridge RS. Technical requirements of a home hemodialysis program. Contrib Nephrol 2004; 145:21.",
"     </a>",
"    </li>",
"    <li>",
"     Blagg, CR, Anderson, C. Home preparation and installation for home hemodialysis. In: Dialysis Therapy, Third Edition, Nissenson AR, Fine RN (Eds), Hanley &amp; Bleifus, Philadelphia 2002. p.87.",
"    </li>",
"    <li>",
"     AAMI. ANSI/AAMI RD52:2004/A1:2007. Dialysate for hemodialysis, Amendment 1 - Annex C: Special considerations for home hemodialysis. 2008. American Association for Medical Instrumentation, Arlington, VA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/21\">",
"      Verhallen AM, Kooistra MP, van Jaarsveld BC. Cannulating in haemodialysis: rope-ladder or buttonhole technique? Nephrol Dial Transplant 2007; 22:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25286/abstract/22\">",
"      Murcutt G. Buttonhole cannulation: should this become the default technique for dialysis patients with native fistulas? Summary of the EDTNA/ERCA Journal Club discussion Autumn 2007. J Ren Care 2008; 34:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1875 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25286=[""].join("\n");
var outline_f24_44_25286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12850220\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELEMENTS OF A HOME HEMODIALYSIS PROGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Objectives of the home hemodialysis training program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Identification of home hemodialysis candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Specific requirements for home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiation of dialysis therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predischarge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ongoing support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12850220\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25287="Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information";
var content_f24_44_25287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/48/29444?source=see_link\">",
"    see \"Aluminum hydroxide, magnesium hydroxide, and simethicone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alamag Plus [OTC];",
"     </li>",
"     <li>",
"      Aldroxicon I [OTC];",
"     </li>",
"     <li>",
"      Aldroxicon II [OTC];",
"     </li>",
"     <li>",
"      Almacone&reg; Double Strength [OTC];",
"     </li>",
"     <li>",
"      Almacone&reg; [OTC];",
"     </li>",
"     <li>",
"      Gelusil&reg; [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Advanced Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Advanced Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Mi-Acid Maximum Strength [OTC] [DSC];",
"     </li>",
"     <li>",
"      Mi-Acid [OTC];",
"     </li>",
"     <li>",
"      Mintox Plus [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Classic Maximum Strength Liquid [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Classic Regular Strength Liquid [OTC];",
"     </li>",
"     <li>",
"      Rulox  [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diovol Plus&reg;;",
"     </li>",
"     <li>",
"      Gelusil&reg;;",
"     </li>",
"     <li>",
"      Mylanta&reg; Double Strength;",
"     </li>",
"     <li>",
"      Mylanta&reg; Extra Strength;",
"     </li>",
"     <li>",
"      Mylanta&reg; Regular Strength",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid;",
"     </li>",
"     <li>",
"      Antiflatulent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dyspepsia, abdominal bloating: Oral: 10-20 mL or 2-4 tablets 4-6 times/day between meals and at bedtime; may be used every hour for severe symptoms",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum and/or magnesium may accumulate in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (360 mL); aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldroxicon I: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldroxicon II: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Almacone&reg;: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains benzyl alcohol, ethanol &lt;0.5%, magnesium 83 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Almacone&reg; Double Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Advanced Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL, 769 mL) [contains magnesium 167 mg/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Advanced Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL, 769 mL) [contains magnesium 167 mg/5 mL; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Advanced Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains magnesium 167 mg/5 mL; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Advanced Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains magnesium 167 mg/5 mL; vanilla cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Advanced Regular Strength: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (360 mL, 780 mL) [contains  magnesium 75 mg/5 mL, potassium 5 mg/5 mL, propylene glycol; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mi-Acid: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mi-Acid Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Classic Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (360 mL, 720 mL) [original, cherry, orange creme, and mint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Classic Regular Strength: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (360 mL) [original and mint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: Aluminum hydroxide 225 mg, magnesium hydroxide 200 mg, and simethicone 25 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rulox: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg per 5 mL (355 mL) [contains magnesium 85 mg/5 mL; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alamag Plus: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg [contains magnesium 83 mg/tablet, phenyalanine 2.6 mg/tablet; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Almacone&reg;: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg [dye free; contains magnesium 82 mg/tablet; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelusil&reg;: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mintox Plus: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg [lemon cr&egrave;me flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 1-2 hours apart from oral drugs; administer 1-3 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of hyperacidity associated with gas; may also be used for indications associated with other antacids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Maalox&reg; may be confused with Maox&reg;, Monodox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mylanta&reg; may be confused with Mynatal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Liquid Maalox&reg; products contain a different formulation than Maalox&reg; Total Relief&reg; which contains bismuth subsalicylate.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Chalky taste, stomach cramps, constipation, bowel motility decreased, fecal impaction, hemorrhoids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Nausea, vomiting, discoloration of feces (white speckles)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dehydration or fluid restriction, hypomagnesemia, hypophosphatemia",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1-3 hours after meals. Some products may contain potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Almacone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg (100): $3.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Gelusil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-25 mg (100): $6.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Mintox Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-25 mg (100): $4.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Almacone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $3.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Di-Gel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     282-87-25 mg/5 mL (360 mL): $3.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Flanax Heartburn Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $3.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (GNP MaSanti Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-400-40 mg/5 mL (355 mL): $4.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (GNP MaSanti Regular Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $4.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maalox Advanced Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-400-40 mg/5 mL (355 mL): $5.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maalox Advanced Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $4.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maalox Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-400-40 mg/5 mL (355 mL): $5.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maalox Multi Symptom Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-400-40 mg/5 mL (769 mL): $9.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maalox Regular Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mi-Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $2.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mintox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $3.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mylanta Double-Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-400-40 mg/5 mL (355 mL): $5.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mylanta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-200-20 mg/5 mL (355 mL): $4.90",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acibiogel (CO);",
"     </li>",
"     <li>",
"      Acitral (ID);",
"     </li>",
"     <li>",
"      Dexanta (ID);",
"     </li>",
"     <li>",
"      Eviline (HK);",
"     </li>",
"     <li>",
"      Gelusil Plus (TW);",
"     </li>",
"     <li>",
"      Gelusil-S (ZA);",
"     </li>",
"     <li>",
"      Hydrosil (HK);",
"     </li>",
"     <li>",
"      Maalox Plus (CN, GR, MY);",
"     </li>",
"     <li>",
"      Mylanta (AU, NZ, SG)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8616 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25287=[""].join("\n");
var outline_f24_44_25287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132556\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132557\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132567\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132559\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132560\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132561\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132548\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132538\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132550\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132549\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132571\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132565\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298726\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132544\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287001\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287002\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132553\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322977\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132554\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/48/29444?source=related_link\">",
"      Aluminum hydroxide, magnesium hydroxide, and simethicone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25288="Pathogenesis of nontuberculous mycobacterial infections";
var content_f24_44_25288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of nontuberculous mycobacterial infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25288/contributors\">",
"     David E Griffith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25288/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25288/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/44/25288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacteria other than M. tuberculosis and M. leprae are generally free-living organisms that are ubiquitous in the environment (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). They have been recovered from surface water, tap water, soil, domestic and wild animals, milk, and food products. Although nontuberculous mycobacteria (NTM) can inhabit body surfaces and secretions without causing disease, they can, in broad terms, induce four distinct clinical syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive pulmonary disease is usually associated with bronchiectasis or chronic obstructive lung disease and caused primarily by M. avium complex (MAC) M. kansasii and M. abscessus, especially in older persons.",
"     </li>",
"     <li>",
"      Superficial lymphadenitis, especially cervical lymphadenitis, in children is caused mostly by MAC, M. scrofulaceum, and, in northern Europe, M. malmoense (M. tuberculosis is a more common cause of lymphadenitis in tuberculosis-endemic countries).",
"     </li>",
"     <li>",
"      Disseminated disease can occur in severely immunocompromised patients.",
"     </li>",
"     <li>",
"      Skin and soft tissue infection usually is a consequence of direct inoculation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of NTM infections will be discussed here. An overview of NTM infections in HIV-negative and HIV-positive patients, as well as the microbiology, epidemiology, diagnosis, and treatment of NTM infections are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15512?source=see_link\">",
"     \"Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PULMONARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of lung disease due to NTM is poorly understood. Pulmonary infection with NTM is probably acquired by inhalation, most likely aerosols from natural surface water or from domestic and institutional hot water systems. In one study, a high rate of gastroesophageal reflux was observed in patients with MAC lung disease, which raises the possibility that initial acquisition may be through ingestion with subsequent aspiration from the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/1\">",
"     1",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Comparative studies with tuberculosis (TB) in the pre-HIV era established that the granulomatous lesions caused by different species of mycobacteria were indistinguishable to trained pathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Therefore, it is presumed that there are substantial similarities to the pathogenesis of TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Host response to MAC infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that pulmonary Mycobacterium avium complex (MAC) disease is relatively rare, despite the high prevalence of skin test reactivity to M. avium complex (MAC) in young adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/4\">",
"     4",
"    </a>",
"    ], suggests that the host immune response is highly effective at containing or eliminating the infecting microbes. Both age and preexisting lung disease or lung injury are major risk factors for active NTM lung disease. With the exception of patients with cystic fibrosis, pulmonary NTM disease is most frequent in older adults. It is not known to what extent NTM disease results from reactivation of latent infection versus exogenous reinfection.",
"   </p>",
"   <p>",
"    If inhaled MAC survive their initial encounter with alveolar macrophages, blood-borne host defenses are called into play, most importantly lymphocytes and monocytes that differentiate into macrophages. In general terms, MAC is taken up by macrophages and survives and proliferates within vacuoles in their cytoplasm as an intracellular pathogen. Mycobacterial products induce apoptosis of macrophages, possibly by downregulation of the Bcl-2 gene product that normally inhibits apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphocytes ultimately interact with the infected macrophages to induce intracellular destruction of the mycobacteria or to destroy the infected macrophage itself. T helper lymphocytes are the basis of acquired (antigen-specific) immunity, while natural killer (NK) cells are key components of the innate immune response to these pathogens. This interaction between macrophage, lymphocyte, and microbe is the focal point in the pathogenesis and immunology of MAC infection that leads to granuloma formation, successful control of the infection, or clinical disease. This chain of events is similar to those described for tuberculosis. It is not yet known, however, if NTM infection leads to latent infection that later causes reactivation disease or if most NTM lung disease is the result of primary infection.",
"   </p>",
"   <p>",
"    In more specific terms, macrophages bind to MAC through fibronectin receptors, receptors for mannosyl and fucosyl moieties of the mycobacterial cell wall, and complement receptor 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Thus, serum enhances phagocytosis of mycobacteria through complement bound to the mycobacterial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/9\">",
"     9",
"    </a>",
"    ]. Bound mycobacteria are taken up in primary phagosomes that fuse with vacuoles in the phagocyte's cytoplasm and attempt to destroy its contents through acidification, toxic oxygen metabolites, defensins (in neutrophils, small protein molecules that disrupt the bacterial cell wall), and possibly other mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages also elaborate cytokines and other chemical messengers that recruit lymphocytes and other macrophages to the site of the infection, leading to interactions between these cell types that enhance killing of these microorganisms. Interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-alpha) are especially important in the antimycobacterial immune response.",
"   </p>",
"   <p>",
"    Macrophages that phagocytize mycobacteria respond with production of IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/12\">",
"     12",
"    </a>",
"    ], which activates T lymphocytes, and NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. NK cells are lymphocytes that destroy certain neoplastic or infected cells, targeting cells with a paucity of major histocompatibility complex (MHC) class I surface molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/15\">",
"     15",
"    </a>",
"    ]. NK cells responding to intracellular and extracellular MAC are stimulated by IL-2, IL-12, and TNFa to release granules containing cytotoxic enzymes that lyse infected cells and also to secrete TNFa and interferon (IFN)-gamma, which augment macrophage mycobactericidal capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of IL-12 results in transcription of IL-12 responsive genes, in particular IFN-gamma. IFN-gamma activates neutrophils and macrophages to produce superoxide and nitric oxide, increases surface display of MHC molecules and Fc receptors, decreases lysosomal pH, and increases the intracellular concentration of certain antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. IFN-gamma signals ultimately influence IFN-gamma responsive genes such as IL-12, MHC genes, and TNFa [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. The positive feedback loop between IFN-gamma and IL-12 is pivotal in the immune response to mycobacteria. Defects in any of these receptors or cytokine genes may negatively affect the production of IFN-gamma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IL-12 and consequently enhance mycobacterial susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of this pathway in susceptibility to infection due to otherwise poorly pathogenic mycobacteria (non-tuberculous mycobacteria or Mycobacterium bovis BCG) is borne out in genetic studies of patients with severe infections due to these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/23\">",
"     23",
"    </a>",
"    ]. Many of these patients are unable to produce or respond to IFN-gamma, due to mutations in genes that encode major proteins in the type 1 cytokine pathway. Similarly, in studies of adults of Asian origin, disseminated nontuberculous mycobacterial infection has been associated with the presence of neutralizing auto-antibodies to IFN-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TNF-alpha is produced by activated macrophages and NK cells and is also an important immune modulator for controlling mycobacterial infection. TNFa has a significant additive effect on macrophage killing of MAC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/25\">",
"     25",
"    </a>",
"    ]. The release of TNF-alpha is stimulated by and is probably responsible for the antimycobacterial effects of IFN-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there are limited published data, it appears that TNF-alpha inhibitors used in the treatment of rheumatoid arthritis and other chronic inflammatory conditions may significantly exacerbate or worsen nontuberculous mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-2 greatly augments the capacity of NK cells to lyse MAC-infected monocytes; NK cells stimulated by IL-2 also enhance intracellular monocyte killing of MAC, again, likely via TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/27\">",
"     27",
"    </a>",
"    ]. As above, IL-12 is a major stimulant for T lymphocytes and NK cells to produce IFN-gamma and TNF-alpha; IL-12 release, in turn, is stimulated by IFN-gamma and TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Granulocyte-macrophage colony stimulation factor (GM-CSF) is produced by MAC-infected monocytes and NK cells and appears to augment mycobacterial killing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, IL-6 and IL-10 down-modulated the inflammatory response, especially the effect of TNF-alpha, and are therefore permissive factors for proliferation of intracellular mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages also process mycobacterial antigens and present them on their surface in conjunction with MHC class I and class II molecules to T lymphocytes. This results in tremendous expansion of T lymphocyte clones that specifically recognize those antigens and forms the basis of both acquired immune responses and immunologic memory that are central to host defense against mycobacteria. This process is exemplified by the delayed hypersensitivity response elicited by the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    . T helper (CD4) lymphocytes recruited to the site of mycobacterial infection secrete IL-2 and interferon gamma that activate macrophages and enhance cytotoxic lymphocyte activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These dynamic cellular events are mirrored histopathologically in the formation of granulomas in which infected foci become surrounded by mononuclear inflammatory cells and epithelioid histiocytes. However, the release of cytolytic enzymes and other cytotoxic proteins ultimately may result in the necrosis and encapsulating fibrosis of both infected and adjacent tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/33\">",
"     33",
"    </a>",
"    ]. These events lead to two major forms of pulmonary MAC disease in adults, the fibrocavitary and fibronodular forms described below.",
"   </p>",
"   <p>",
"    Mycobacteria have evolved to protect themselves from the host immune response. Components of the mycobacterial cell wall scavenge reactive oxygen intermediates, block acidification of the phagocytic vacuoles, suppress the synthesis of cytokines, and downregulate lymphocyte proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. MAC isolates differ in their ability to protect themselves from host immune responses. Although the molecular basis for these differences has not been established, isolates with smooth-domed colony morphology are less pathogenic than those with smooth-transparent colony morphology. MAC of the smooth-domed colony types elicit greater production of inflammatory cytokines, while smooth-transparent colonial types tend to be relatively silent immunologically causing little production of cytokines and less vigorous host responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune modulators act in a complicated fashion, and it is difficult to isolate and measure any single aspect of the complicated inflammatory cascade in vivo. However, understanding these processes can produce practical results as illustrated by a family with a monocyte defect in IL-12 production that was associated with disseminated MAC infection in the absence of HIV infection. This defect was overcome by exogenous administration of IFN-gamma in addition to other antimycobacterial therapy, resulting in successful treatment of the disseminated MAC infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Identification of specific genetic defects in the IFN-gamma and IL-12 response pathways, especially receptor deficiencies, has elucidated key pathways in immune surveillance and NTM control and identified other patients at risk for disseminated NTM infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/41\">",
"     41",
"    </a>",
"    ]. To date, however, no specific immune deficiency has been identified for patients with NTM lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fibrocavitary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung disease due to MAC has been recently differentiated into two distinct forms, fibrocavitary and fibronodular (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    ). In the more familiar fibrocavitary form, upper lobe disease occurs most commonly in elderly male smokers with chronic pulmonary symptoms due to underlying lung disease. Symptoms and radiographic changes may be difficult to differentiate from the underlying disease, but MAC is often easily recovered from the sputum of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fibronodular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibronodular and bronchiectatic form of MAC lung disease appears most frequently in nonsmoking women over the age of 50 who do not have underlying lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Body morphotype is a possible predisposition to this second form of disease. Some patients with fibronodular NTM lung disease appear to have similar clinical characteristics and body types, including scoliosis, pectus excavatum, mitral valve prolapse, and joint hypermobility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The constellation of phenotypic abnormalities seen in pulmonary NTM disease may represent a forme fruste of a connective tissue disease hitherto unidentified and associated with NTM pulmonary disease. The mechanism by which this body morphotype predisposes to pulmonary mycobacterial infection is not defined, but poor secretion drainage and ineffective mucociliary clearance are possible explanations.",
"   </p>",
"   <p>",
"    There is also emerging evidence that some of these patients may be predisposed to NTM lung disease because of preexisting bronchiectasis. Some potential etiologies for bronchiectasis in this population include gastroesophageal reflux with chronic aspiration, alpha-1 antitrypsin deficiency, and cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Of particular interest are patients with bronchiectasis and MAC lung disease who are heterozygous for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/46\">",
"     46",
"    </a>",
"    ]. Single CFTR mutations appear to occur more frequently in selected populations of MAC patients with bronchiectasis. Although these patients do not meet criteria for frank cystic fibrosis, there is some evidence that they have bronchial epithelial ion and water transport abnormalities that might be a mechanism for the development of bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographically, multiple small nodules and fibrosis, associated with cylindrical bronchiectasis, are visible in the mid-lung fields by high-resolution computed tomography (HRCT); this combination of findings is highly suggestive of MAC infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/49\">",
"     49",
"    </a>",
"    ]. Pathologically, these nodules represent granulomatous inflammation.",
"   </p>",
"   <p>",
"    Shedding of MAC into the respiratory secretions in these patients is less consistent than in the fibrocavitary form of the disease. Sputa may be intermittently positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive with low numbers of organisms. Therefore, prior to the advent of HRCT, isolation of MAC from the sputum of such patients was frequently dismissed as \"colonization.\" Further study, however, has demonstrated that this condition may progress to respiratory failure. For example, in one report of 21 such patients, four (19 percent) had progressive disease during longitudinal follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mycobacterium kansasii infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. kansasii lung disease most closely resembles typical TB in its clinical and radiographic features. Older age, male sex, smoking, and underlying lung disease are common features. Unlike most NTM, M. kansasii is not an environmental contaminant or colonizer (M. kansasii, so far, has been isolated only from municipal water supplies); thus, even a single positive culture may be considered diagnostic of disease (although diagnosis of M. kansasii lung disease should still be based on ATS diagnostic criteria).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rapidly growing mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly growing mycobacteria, especially M. fortuitum and M. abscessus, also cause lung disease. In contrast to the fibrocavitary form of MAC and M. kansasii, affected patients tend to be females, nonsmokers, and do not have preexisting lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/50\">",
"     50",
"    </a>",
"    ]. Noteworthy exceptions include cystic fibrosis, prior granulomatous disease, lipoid pneumonia, and esophageal dysmotility (eg, achalasia) with chronic vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. As in other forms of NTM lung disease, symptoms are indolent and include cough, fever, and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. simiae, M. xenopi, and M. malmoense have also been reported to cause chronic progressive granulomatous lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. The pathogenesis of these infections, as distinct from tuberculosis and MAC lung disease, has not been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISSEMINATED DISEASE IN HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM infection in patients with AIDS primarily presents as disseminated disease in association with very low CD4 lymphocyte counts (usually below",
"    <span class=\"nowrap\">",
"     100/microL)",
"    </span>",
"    in developed countries. Exposure has been documented from potable hot water [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/55\">",
"     55",
"    </a>",
"    ]. Disseminated NTM disease occurred in 5.5 percent of AIDS cases reported to the Centers for Disease Control and Prevention (CDC) from 1981 to 1987, 96 percent of which were due to MAC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/56\">",
"     56",
"    </a>",
"    ]. However, effective MAC prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , as well as the advent of highly active antiretroviral therapy, has led to a decline in the incidence of disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\", section on 'Disseminated disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial observations on disseminated MAC disease in patients with AIDS found that heavy bacteremia, widespread disease, and a high tissue burden of organisms were typical [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/57\">",
"     57",
"    </a>",
"    ]. However, these reports focused on the more severe and conspicuous manifestations of this disease. More recent data have demonstrated that this illness develops progressively from bacteremia arising from initially localized infection, especially from a respiratory or gastrointestinal source [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. In one large series, among AIDS patients with CD4 lymphocytes",
"    <span class=\"nowrap\">",
"     &lt;50/mL,",
"    </span>",
"    nearly 60 percent of those with respiratory or fecal MAC developed MAC bacteremia within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/58\">",
"     58",
"    </a>",
"    ]. The risk of MAC bacteremia was increased 2.3-fold for patients with respiratory MAC and 6.0-fold for patients with fecal MAC compared to those without respiratory or fecal MAC, respectively. Patients may be infected simultaneously with two different strains of MAC and these strains may have different susceptibility patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At first, bacteremia from these localized infections may be infrequent and intermittent. In patients followed with serial blood cultures through death and postmortem examination, the tissue burden of organisms and the number of tissues involved increased in direct proportion to the time after the initial positive blood cultures and to the fraction of blood cultures that were positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/59\">",
"     59",
"    </a>",
"    ]. Disseminated MAC in AIDS is very rare in countries in which tuberculosis is endemic despite the presence of MAC in the environment and skin test evidence of MAC exposure in these regions. These observations suggest a role for cross-protective immunity from childhood BCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    latent TB [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the pathogenetic model proposes that mycobacteria from the environment infect a mucosal surface (gut or lung), multiply locally, and eventually enter the bloodstream and disseminate, seeding other organs and tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25288/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. As metastatic foci of infection progress, bacteremia becomes more constant and heavier, and tissue involvement increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8892280\">",
"    <span class=\"h1\">",
"     LYMPHADENITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM can cause lymphadenitis, primarily in children younger than five years of age. The frequent involvement of cervical lymph nodes suggests that ingestion and direct tissue penetration by the organism is the usual pathogenesis of this disease. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642373090\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacteria other than M. tuberculosis and M. leprae are generally free-living organisms that are ubiquitous in the environment (",
"      <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"       table 1",
"      </a>",
"      ). They have been recovered from surface water, tap water, soil, domestic and wild animals, milk, and food products. Although nontuberculous mycobacteria (NTM) can inhabit body surfaces and secretions without causing disease, they can, in broad terms, induce four distinct clinical syndromes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary disease is usually associated with bronchiectasis or chronic obstructive lung disease and caused primarily by M. avium complex (MAC) M. kansasii and M. abscessus, especially in older persons.",
"     </li>",
"     <li>",
"      Superficial lymphadenitis, especially cervical lymphadenitis, in children is caused mostly by MAC, M. scrofulaceum, and, in northern Europe, M. malmoense (M. tuberculosis is a more common cause of lymphadenitis in tuberculosis-endemic countries).",
"     </li>",
"     <li>",
"      Disseminated disease can occur in severely immunocompromised patients.",
"     </li>",
"     <li>",
"      Skin and soft tissue infection usually is a consequence of direct inoculation. (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary infection with NTM is probably acquired by inhalation, most likely aerosols from natural surface water or from domestic and institutional hot water systems. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pulmonary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The observation that pulmonary M. avium complex (MAC) disease is relatively rare, despite the high prevalence of skin test reactivity to MAC in young adulthood, suggests that the host immune response is highly effective at containing or eliminating the infecting microbes. If inhaled MAC survive their initial encounter with alveolar macrophages, blood-borne host defenses are called into play, most importantly lymphocytes and monocytes that differentiate into macrophages. MAC is taken up by macrophages and survives and proliferates within vacuoles in their cytoplasm as an intracellular pathogen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Host response to MAC infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphocytes ultimately interact with the infected macrophages to induce intracellular destruction of the mycobacteria or to destroy the infected macrophage itself. T helper lymphocytes are the basis of acquired (antigen-specific) immunity, while natural killer (NK) cells are key components of the innate immune response to these pathogens. This interaction between macrophage, lymphocyte, and microbe is the focal point in the pathogenesis and immunology of MAC infection that leads to granuloma formation, successful control of the infection, or clinical disease. This chain of events is similar to those described for tuberculosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Host response to MAC infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NTM infection in patients with AIDS primarily presents as disseminated disease in association with very low CD4 lymphocyte counts (usually below",
"      <span class=\"nowrap\">",
"       100/microL).",
"      </span>",
"      In such patients, mycobacteria from the environment infect a mucosal surface (gut or lung), multiply locally, and eventually enter the bloodstream and disseminate, seeding other organs and tissues. As metastatic foci of infection progress, bacteremia becomes more constant and heavier, and tissue involvement increases. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disseminated disease in HIV-infected patients'",
"      </a>",
"      above.) Disseminated NTM disease is also seen in patients with rare genetic defects that alter IL-12 and IFN-gamma production and in association with TNF-alpha inhibitors.",
"     </li>",
"     <li>",
"      NTM can cause lymphadenitis, primarily in children younger than five years of age. The frequent involvement of cervical lymph nodes suggests that ingestion and direct tissue penetration by the organism is the usual pathogenesis of this disease. (See",
"      <a class=\"local\" href=\"#H8892280\">",
"       'Lymphadenitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/1\">",
"      Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 131:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/2\">",
"      Good RC, Snider DE Jr. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/3\">",
"      CORPE RF, STERGUS I. Is the histopathology of nonphotochromogenic mycobacterial infections distinguishable from that caused by Mycobacterium tuberculosis? Am Rev Respir Dis 1963; 87:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/4\">",
"      von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/5\">",
"      Hayashi T, Catanzaro A, Rao SP. Apoptosis of human monocytes and macrophages by Mycobacterium avium sonicate. Infect Immun 1997; 65:5262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/6\">",
"      Klingler K, Tchou-Wong KM, Br&auml;ndli O, et al. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun 1997; 65:5272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/7\">",
"      Bermudez LE, Young LS, Enkel H. Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun 1991; 59:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/8\">",
"      Roecklein JA, Swartz RP, Yeager H Jr. Nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages. J Lab Clin Med 1992; 119:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/9\">",
"      Swartz RP, Naai D, Vogel CW, Yeager H Jr. Differences in uptake of mycobacteria by human monocytes: a role for complement. Infect Immun 1988; 56:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/10\">",
"      Holland SM. Host defense against nontuberculous mycobacterial infections. Semin Respir Infect 1996; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/11\">",
"      Ogata K, Linzer BA, Zuberi RI, et al. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992; 60:4720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/12\">",
"      Fulton SA, Johnsen JM, Wolf SF, et al. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis. Infect Immun 1996; 64:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/13\">",
"      Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/14\">",
"      Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999; 238:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/15\">",
"      Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995; 82:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/16\">",
"      Blanchard DK, Michelini-Norris MB, Friedman H, Djeu JY. Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1. Cell Immunol 1989; 119:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/17\">",
"      Katz P, Yeager H Jr, Whalen G, et al. Natural killer cell-mediated lysis of Mycobacterium-avium complex-infected monocytes. J Clin Immunol 1990; 10:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/18\">",
"      Bermudez LE, Young LS. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb Pathog 1989; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/19\">",
"      Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/20\">",
"      Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/21\">",
"      Darnell JE Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998; 18:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/22\">",
"      Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/23\">",
"      van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004; 4:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/24\">",
"      Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/25\">",
"      Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/26\">",
"      Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/27\">",
"      Bermudez LE, Young LS. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 1991; 146:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/28\">",
"      Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/29\">",
"      Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995; 63:4099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/30\">",
"      Bermudez LE, Martinelli J, Petrofsky M, et al. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 1994; 169:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/31\">",
"      Denis M. Interleukin-6 is used as a growth factor by virulent Mycobacterium avium: presence of specific receptors. Cell Immunol 1992; 141:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/32\">",
"      Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993; 61:3093.",
"     </a>",
"    </li>",
"    <li>",
"     Dannenberg AM Jr, Rook GAW. Pathogenesis of pulmonary tuberculosis: An interplay of tissue-damaging and macrophage-activating immune responses &mdash; dual mechanisms that control bacillary multiplications. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed), ASM Press, Washington, DC 1994. p.459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/34\">",
"      Chan J, Fan XD, Hunter SW, et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/35\">",
"      Hines ME 2nd, Jaynes JM, Barker SA, et al. Isolation and partial characterization of glycolipid fractions from Mycobacterium avium serovar 2 (Mycobacterium paratuberculosis 18) that inhibit activated macrophages. Infect Immun 1993; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/36\">",
"      Tsuyuguchi I, Kawasumi H, Takashima T, et al. Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity. Infect Immun 1990; 58:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/37\">",
"      Shiratsuchi H, Toossi Z, Mettler MA, Ellner JJ. Colonial morphotype as a determinant of cytokine expression by human monocytes infected with Mycobacterium avium. J Immunol 1993; 150:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/38\">",
"      Michelini-Norris MB, Blanchard DK, Pearson CA, Djeu JY. Differential release of interleukin (IL)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of Mycobacterium avium-intracellulare complex. J Infect Dis 1992; 165:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/39\">",
"      Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/40\">",
"      Frucht DM, Holland SM. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol 1996; 157:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/41\">",
"      Guide SV, Holland SM. Host susceptibility factors in mycobacterial infection. Genetics and body morphotype. Infect Dis Clin North Am 2002; 16:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/42\">",
"      Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/43\">",
"      Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/44\">",
"      Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/45\">",
"      Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991; 144:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/46\">",
"      Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/47\">",
"      Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/48\">",
"      Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/49\">",
"      Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/50\">",
"      Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/51\">",
"      Wallace RJ Jr. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae. Clin Chest Med 1989; 10:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/52\">",
"      Alberts WM, Chandler KW, Solomon DA, Goldman AL. Pulmonary disease caused by Mycobacterium malmoense. Am Rev Respir Dis 1987; 135:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/53\">",
"      Costrini AM, Mahler DA, Gross WM, et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981; 123:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/54\">",
"      Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/55\">",
"      von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994; 343:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/56\">",
"      Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/57\">",
"      Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/58\">",
"      Chin DP, Hopewell PC, Yajko DM, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/59\">",
"      Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991; 164:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/60\">",
"      Torriani FJ, McCutchan JA, Bozzette SA, et al. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994; 170:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/61\">",
"      Torriani FJ, Behling CA, McCutchan JA, et al. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis 1996; 173:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/62\">",
"      von Reyn CF, Jacobs NJ, Arbeit RD, et al. Polyclonal Mycobacterium avium infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient. J Clin Microbiol 1995; 33:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/63\">",
"      Fordham von Reyn C, Arbeit RD, Tosteson AN, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. AIDS 1996; 10:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25288/abstract/64\">",
"      von Reyn CF, Barber TW, Arbeit RD, et al. Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellulare complex among healthy subjects: an international study of dominant mycobacterial skin test reactions. J Infect Dis 1993; 168:1553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5345 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-304210EFA6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25288=[""].join("\n");
var outline_f24_44_25288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1642373090\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PULMONARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Host response to MAC infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fibrocavitary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fibronodular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mycobacterium kansasii infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rapidly growing mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISSEMINATED DISEASE IN HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8892280\">",
"      LYMPHADENITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1642373090\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15512?source=related_link\">",
"      Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25289="Arthritis associated with gastrointestinal disease";
var content_f24_44_25289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arthritis associated with gastrointestinal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25289/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/44/25289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis is a recognized extraintestinal manifestation of several illnesses and conditions, including inflammatory bowel disease (IBD), bacterial infections of the gut, gluten sensitive enteropathy (celiac disease), various parasitic infections, pseudomembranous colitis, and following intestinal bypass surgery. Other illnesses have a propensity for causing inflammation of joints and the gut. Examples discussed in this review include Beh&ccedil;et&rsquo;s and Whipple's diseases.",
"   </p>",
"   <p>",
"    The clinical features of arthritis associated with IBD are discussed in detail here, along with the treatment for synovitis in patients with Crohn's disease and ulcerative colitis. The pathogenesis of these manifestations and the treatment of IBD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=see_link\">",
"     \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy for reactive arthritis (formerly called Reiter syndrome), Beh&ccedil;et&rsquo;s and Whipple's diseases are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link&amp;anchor=H28#H28\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link&amp;anchor=H12#H12\">",
"     \"Whipple's disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND ASSOCIATED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis occurs in 9 to 53 percent of patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. Arthritis is somewhat more likely to occur in patients with large-bowel disease and in those patients with complications such as abscesses, pseudomembranous polyposis, perianal disease, massive hemorrhage, erythema nodosum, stomatitis, uveitis, and pyoderma gangrenosum. Among patients with Crohn's disease, those with colonic involvement are at higher risk of developing synovitis than those with isolated small bowel disease. Males and females are affected equally. Both children and adults are at risk for this complication of IBD. In addition subclinical gut inflammation, documented by endoscopy, has been described in up to two-thirds of patients with spondyloarthropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ULCERATIVE COLITIS AND CROHN'S DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis and regional enteritis (Crohn's disease) are the most frequently encountered types of idiopathic IBD that are associated with arthritis or spondylitis and are discussed first. Other disorders associated with joint pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation are discussed later. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Other diseases with bowel and joint involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis may affect the spine, sacroiliac joints, appendicular joints, or a combination of these articulations. Peripheral arthritis may be acute and remitting (Type I), or be a more chronic problem or have frequent relapses (Type II) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"     11",
"    </a>",
"    ]. Complications of IBD may also cause joint pain and must be distinguished from sterile inflammation. Bacterial infection of the sacroiliac or peripheral joints may occur due to fistulization or bacteremia. Adverse effects of treatment of IBD may also affect joints. Osteonecrosis (avascular necrosis of bone) due to glucocorticoid use is one example. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Spondylitis and sacroiliitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondylitis occurs in 1 to 26 percent of patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/1-4,7,12\">",
"     1-4,7,12",
"    </a>",
"    ]. Males are more frequently affected than females. Patients typically complain of prolonged stiffness in the back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    buttocks in the morning or after rest. Stiffness and associated pain are often relieved by exercise. Back symptoms are unrelated to those of the gastrointestinal disease. Physical examination may reveal limited spinal flexion and reduced chest expansion. Spondylitis may be the only articular manifestation or it may occur in association with type I peripheral arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"     11",
"    </a>",
"    ], which is discussed below.",
"   </p>",
"   <p>",
"    Asymptomatic sacroiliitis, detected by radiography, occurs in 4 to 18 percent of patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/12\">",
"     12",
"    </a>",
"    ]. By contrast, 52 percent of patients with IBD have abnormal technetium pyrophosphate bone scans of the sacroiliac joints [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. No increased frequency of HLA-B27 in the subset of patients with IBD and radiographic sacroiliitis was apparent in this study.",
"   </p>",
"   <p>",
"    In contrast, sacroiliitis in patients with Crohn's disease is strongly associated with CARD15 gene polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study of 102 patients with Crohn's disease, 23 were found to have radiological evidence of sacroiliitis. Although only three of these patients were HLA-B27 positive, 78 percent of those with sacroiliitis had a CARD15 variant, compared with only 48 percent of those who did not have sacroiliitis (odds ratio 3.8).",
"   </p>",
"   <p>",
"    The presence of an abnormal radiograph of the sacroiliac joints does not indicate a higher risk for the development of spondylitis. Magnetic resonance imaging can also reveal changes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69296 \" href=\"UTD.htm?4/56/5000\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Type I arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type I arthropathy, the peripheral arthritis tends to be acute, is pauciarticular (affecting six or fewer joints), is often associated with flares of the bowel disease, occurs early in the course of the bowel disease, is self-limiting (90 percent under 6 months), and does not result in joint deformities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. The knee is most commonly affected. Five percent of IBD patients develop type I arthropathy. Joint symptoms may occur prior to the onset of symptoms suggestive of bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Type II arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Type II arthropathy, patients have polyarticular disease, with metacarpophalangeal (MCP) joints being particularly involved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"     11",
"    </a>",
"    ]. Other joints (knees, ankles, elbows, shoulders, wrists, proximal interphalangeal (PIP), and metatarsophalangeal (MTP) joints) are less often affected. Approximately one half of the patients with IBD have migratory arthritis. Active synovitis may persist for months, and may recur repeatedly. Episodes of exacerbations and remissions may continue for years.",
"   </p>",
"   <p>",
"    Type II arthropathy affects 3 to 4 percent of patients with IBD. Articular involvement rarely precedes the diagnosis of IBD and joint symptoms typically do not parallel the activity of bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral white blood cell count, hematocrit, erythrocyte sedimentation rate, and serum C-reactive protein concentration usually reflect the activity of the intestinal disease and are therefore of little help in assessing arthritis or spondylitis. Serum levels of rheumatoid factor are not elevated.",
"   </p>",
"   <p>",
"    HLA-B27 is found in 50 to 75 percent of the patients with axial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/4\">",
"     4",
"    </a>",
"    ]. An increase in frequency in HLA-B27, B35, and DRB1*0103 has been described in those with a type I peripheral arthritis; type II arthropathy has been associated with HLA-B44 (and not B27) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"     11",
"    </a>",
"    ]. While the reported HLA associations are of interest, HLA typing has no role in management of individual patients.",
"   </p>",
"   <p>",
"    Synovial fluids have yielded from 5000 to 12,000 white blood cells per microliter, predominantly polymorphonuclear leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Synovial membrane biopsies reveal nonspecific abnormalities, including: proliferation of synovial lining cells, increased vascularity, and infiltration of mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs of the spine and pelvis may show typical findings of ankylosing spondylitis and sacroiliitis. Plain film radiographs of the peripheral joints demonstrate soft-tissue swelling, juxtaarticular osteoporosis, mild periostitis, and effusions, usually without erosions or destruction. Radiographs frequently have abnormal findings even in asymptomatic patients with IBD. In one study, for example, plain film and computer aided tomography (CT) were used to evaluate the sacroiliac joints of 65 patients with IBD, none of whom had symptoms of sacroiliitis; 18 percent had finding of sacroiliitis by plain film and 32 percent had had abnormal sacroiliac joints noted by CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no pathognomonic finding to confirm the clinical suspicion of arthritis due to IBD. While the diagnosis may be suspected in the proper clinical setting, it remains largely one of exclusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .) If the arthritis affects a single joint (monoarthritis), or a few joints (oligoarthritis), it is particularly important to perform a joint aspiration to exclude septic arthritis, the presentation of which may be atypical in patients with IBD who are receiving antiinflammatory or immunosuppressive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of joint pain in a patient with IBD is broad. Disorders causing joint pain that may occur with increased frequency in this setting include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic osteoarthropathy with clubbing develops with varying frequency in patients with IBD, being most common in Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/12,16\">",
"       12,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"       \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteonecrosis (avascular necrosis of bone), which commonly affects the hip, knee, and shoulder. Affected patients typically have been treated with glucocorticoids and experience pain that is out of proportion to the degree of limitation of passive range of motion of the affected joint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"       \"Osteonecrosis (avascular necrosis of bone)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septic arthritis, either gonococcal or nongonococcal bacterial infection, or opportunistic infections due to fungi or mycobacteria are considerations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"       \"Septic arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythema nodosum may be difficult to distinguish from arthritis when lesions occur in a periarticular location. Inability to aspirate synovial fluid from a frankly swollen and painful joint is one clue to the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"       \"Erythema nodosum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the disorders listed above, there are other diseases and states that have prominent intestinal manifestations and are associated with arthritis. These include reactive arthritis (formerly Reiter syndrome), Whipple's disease, Beh&ccedil;et&rsquo;s syndrome, intestinal bypass, gluten sensitive enteropathy, and parasitic infestations. Each of these conditions is discussed following the section on treatment of arthritis in IBD. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Other diseases with bowel and joint involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective treatment of the underlying IBD is often helpful in controlling the peripheral arthritis. Spinal involvement is more problematic and no therapy has been definitively shown to slow the radiographic progression of spondylitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Peripheral arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some agents, notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercaptopurine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , glucocorticoids, and tumor necrosis factor (TNF) inhibitors may be helpful for both bowel and joint inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. NSAIDs may relieve the arthritic symptoms, but may have an adverse effect on the IBD. There is only limited information from randomized trials to guide treatment decisions for arthritis associated with inflammatory bowel disease; most of the available information is from small case series. Our recommendations are based upon the available evidence, inferences from studies of other forms of arthritis, including spondyloarthritis and reactive arthritis, and our clinical experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs &mdash; Nonsteroidal antiinflammatory drugs (NSAIDs) relieve pain and inflammation, but should be used with caution because of possible gastrointestinal side effects. Although careful epidemiologic studies investigating the possible link between NSAIDs and the development of IBD have not been performed, a number of reports suggest that NSAIDs increase the risk for the development of IBD and may exacerbate underlying IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/7,17,23,24\">",
"       7,17,23,24",
"      </a>",
"      ]. However, some patients with IBD appear to be able to tolerate NSAIDs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"       \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"       \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The new onset of symptoms of IBD or worsening of previously diagnosed bowel disease in a patient whose arthritis is being treated with NSAIDs presents a challenging management problem. Agents effective for treatment of idiopathic IBD may improve bowel inflammation due to NSAIDs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/23\">",
"       23",
"      </a>",
"      ]. Similarly, radiographic studies and even endoscopic findings and biopsies may be unable to differentiate these causes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/23\">",
"       23",
"      </a>",
"      ]. Thus, improvement in symptoms and the mucosal appearance following withdrawal of the potentially offending NSAID may provide the best support for NSAIDs being the cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link&amp;anchor=H10#H10\">",
"       \"NSAIDs: Adverse effects on the distal small bowel and colon\", section on 'Management'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Experience with the cyclooxygenase-2 (COX-2) selective inhibitors, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , is limited in patients with IBD. Because COX-2 activity promotes epithelial proliferation and wound healing, COX-2 inhibition could, theoretically, have deleterious effects in patients with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/25\">",
"       25",
"      </a>",
"      ]. On the other hand, selective COX-2 inhibitors ameliorate the severity of experimental colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/23\">",
"       23",
"      </a>",
"      ]. The only placebo-controlled trial to assess the effect on bowel disease in patients with IBD used celecoxib as the active drug and no significant difference in the rate of relapse of IBD was noted after two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One of the largest studies included 45 patients with IBD and arthralgias who were treated with rofecoxib, which is no longer available, for from three days to three months [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/27\">",
"       27",
"      </a>",
"      ]. Arthralgia relief was reported by 71 percent of patients (complete relief in 18 percent and partial relief in 53 percent). However, nine patients (20 percent) required discontinuation of therapy due to the development of gastrointestinal symptoms, which subsided after treatment was stopped. This was a higher rate of discontinuation than was observed in a control group of 30 patients with dyspepsia (3 percent). The percentage of patients who required discontinuation was similar for those with Crohn's disease or ulcerative colitis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      &mdash; Sulfasalazine is an azo-bonded combination of 5-aminosalicylic acid and sulfapyridine [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/28\">",
"       28",
"      </a>",
"      ]. Sulfasalazine is poorly absorbed in the small intestine. In the colon, sulfasalazine is split by bacteria into its constituent moieties. The 5-amino compound lowers colonic prostaglandin E and alters gut flora. The sulfapyridine appears to be antiarthritic [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunomodulatory agents &mdash; Other immunomodulatory therapies used for IBD, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and 6-mercaptopurine, may also have beneficial effects on joint disease. However, aminosalicylates (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ), which are useful for controlling intestinal inflammation, appear to have no direct antiinflammatory effect on the synovium [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anticytokine therapies &mdash; Anticytokine therapies, particularly those that inhibit tumor necrosis factor alpha (TNF alpha), have been used for treating Crohn's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"       \"Adalimumab for treatment of Crohn's disease in adults\"",
"      </a>",
"      ). These agents have also proven useful for patients with rheumatoid arthritis or reactive arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are as yet only anecdotal reports and small uncontrolled series that address the usefulness of anti-TNF alpha treatment in patients with IBD and peripheral arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/18,21,29,30\">",
"       18,21,29,30",
"      </a>",
"      ]. Additional clinical experience is needed to assess the efficacy and safety of cytokine inhibitors in the treatment of arthritis in patients with IBD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the peripheral arthritis associated with IBD is generally nondestructive, therapy is primarily directed at symptomatic relief.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite concern about the potential for NSAIDs and COX-2 selective agents to cause worsening bowel inflammation, we have used agents from both of these classes successfully in patients with IBD. However, if symptoms or signs of IBD develop or worsen during use of NSAIDs or COX-2 selective treatment, it is prudent to temporarily or permanently discontinue their use.",
"     </li>",
"     <li>",
"      If NSAIDs or COX-2 selective agents do not result in acceptable symptomatic relief, we recommend addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , if it is not already being used to treat bowel disease. The initial dose is 500 mg twice daily with an increase in daily dose of 1000 mg every two weeks until arthritis symptoms improve or a maximum dose of 1500 mg three times daily is reached. Maintaining the maximum dose for up to 12 weeks is recommended before assessing efficacy.",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      is not effective. However, patient or physician concerns about the potential hepatotoxicity of methotrexate may make",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine more attractive alternatives. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"       \"Immunomodulator therapy in Crohn's disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Orally administered methotrexate is adequately absorbed, even in patients with active IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/31\">",
"       31",
"      </a>",
"      ]. Although subcutaneous injection of methotrexate may reduce portal venous concentrations of the drug, it has not been proven that this reduces the risk of hepatotoxicity. If dose limiting gastrointestinal side effects from methotrexate develop during oral therapy, switching to parenteral administration is recommended.",
"      <br/>",
"      <br/>",
"      The dosage used for subcutaneous administration is the same as for oral methotrexate. A typical beginning dose is 7.5 mg per week. The dose is increased in 2.5 to 5 mg increments, at approximately monthly intervals, until joint inflammation is controlled, or a dose of 25 mg per week is reached. Concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , 1 mg per day or weekly folinic acid (racemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      2.5 to 5 mg or L-leucovorin 1 to 2 mg weekly) 24 hours following the methotrexate dose, is recommended to avoid nuisance side effects such as oral ulcers. Supplemental folate or leucovorin may also reduce the risk of myelotoxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or 6-mercaptopurine has not successfully controlled the arthritis, glucocorticoids may be useful, and may be administered either systemically or via intraarticular injection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"       \"Joint aspiration or injection in adults: Technique and indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If polyarticular synovitis persists despite the treatment outlined above, use of a TNF-alpha antagonist, either by intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or subcutaneous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , is recommended. Dosing regimens developed for patients with rheumatoid arthritis are appropriate. Skin testing for latent tuberculosis is mandatory, since use of anti-TNF alpha therapies may cause reactivation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The presence of active infection is an absolute contraindication to the use of either of these cytokine inhibitors. Patients with evidence of latent, previously untreated tuberculosis should begin antituberculous therapy prior to beginning anti-TNF-alpha therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"       \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Spondylitis and sacroiliitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axial disease associated with IBD is treated as is any spondyloarthropathy. The treatment for spinal and sacroiliac involvement is symptomatic, as it is for the peripheral arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .) However, even if back pain and stiffness are controlled, radiographic progression to bony ankylosis may occur. NSAIDs or COX-2 selective agents are used to treat spinal pain and stiffness. The same concerns and cautions that were noted above for peripheral arthritis apply to their use for spondylitis and sacroiliitis.",
"   </p>",
"   <p>",
"    As noted earlier, experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is limited to small case series in which it has been associated with improvement in symptoms of spondylitis as well as peripheral arthritis during treatment with infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/30\">",
"     30",
"    </a>",
"    ]. Whether anti-TNF therapy has any long term effect upon the progression of spondylitis remains to be determined.",
"   </p>",
"   <p>",
"    In selecting among the available anti-TNF therapies, it should be noted that while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    may be used safely, and is reported to be effective for arthritis and spinal involvement in Crohn's disease, it is of no benefit for the intestinal manifestations of that disorder, unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , which is often used for Crohn's disease and complications such as fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic and pharmacologic treatment are complementary for patients with spinal involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The author recommends referral to a physical therapist for instruction in back exercises; these are aimed at prevention of neck and back deformities.",
"     </li>",
"     <li>",
"      Of the available NSAIDs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      have been used successfully, but antiinflammatory doses of any NSAID or COX-2 selective agent may be effective for symptoms of spondylitis or sacroiliitis.",
"     </li>",
"     <li>",
"      For patients refractory to NSAIDs or COX-2 selective agents alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is recommended with dosing as described above for peripheral arthritis. An alternative to methotrexate is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data are limited, it can be expected that sacroiliac and spinal inflammation associated with IBD will respond to anti-TNF therapy as it does in ankylosing spondylitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER DISEASES WITH BOWEL AND JOINT INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to ulcerative colitis and Crohn's disease, several other illnesses and conditions have intestinal involvement and arthritis as prominent clinical features. These include, but are not limited to: reactive arthritis (Reiter syndrome), Whipple's disease, Beh&ccedil;et&rsquo;s disease, celiac disease, parasitic infestation, pseudomembranous colitis, and as a result of intestinal bypass surgery. These disorders are also considerations in the differential diagnosis of patients with suspected IBD and arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis may occur after enteric infection due to Salmonella, Shigella, Yersinia, or Campylobacter species [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/17,34\">",
"     17,34",
"    </a>",
"    ]. The incidence of reactive arthritis following bacterial dysentery has been reported to range from 2 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/2\">",
"     2",
"    </a>",
"    ]. An increased risk of arthritis is associated with Yersinia infection and presence of HLA-B27 genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/1\">",
"     1",
"    </a>",
"    ]. HLA-B27 has been found in over ninety percent of such cases.",
"   </p>",
"   <p>",
"    Joint pain following diarrheal illness due to pathogenic E. coli infection has been noted. This group of E. coli includes enterotoxigenic E. coli (ETEC), attaching and effacing E. coli",
"    <span class=\"nowrap\">",
"     (A/EEC),",
"    </span>",
"    enteropathogenic E. coli (EPEC), and verocytotoxin (shigatoxin)-producing E. coli (VTEC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    .) Unlike reactive joint pain following Salmonella, Shigella, and Yersinia infection, the risk for developing arthralgia following E. coli infection is not affected by HLA-B27 status [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint symptoms develop within two to three weeks of developing diarrhea. The knee, ankle, wrist, and sacroiliac joints are commonly involved. Demonstration of a pathogenic organism by stool culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    finding a rise in antibody titers to the putative organism is helpful in confirming the clinical suspicion of reactive arthritis. Antibiotic treatment may be effective if begun during the diarrheal phase, but is not effective once arthritis is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Whipple's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple's disease is due to infection with Tropheryma whippelii. Infection can be wide spread and may cause diarrhea, malabsorption, and weight loss. Systemic infection is often associated with joint manifestations. The knee, ankle, and wrist are frequently affected. Some patients may develop spondylitis and or sacroiliac joint involvement. In some patients the articular symptoms develop prior to symptomatic enteric involvement. Small bowel biopsy is usually diagnostic. Whipple's disease requires long-term antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Beh&ccedil;et's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is characterized by oral and genital ulceration, iritis, and occasionally by central nervous system involvement. In addition, oligoarticular, asymmetric arthralgia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthritis may develop in approximately 50 percent of patients. The knee, ankle, wrist, and elbow are common sites of involvement. Mucosal ulceration of the small bowel is a frequent manifestation and may cause nausea, diarrhea, abdominal pain, and distension. Beh&ccedil;et&rsquo;s disease may be particularly difficult to distinguish from IBD. The presence of pathergy, sterile neutrophilic infiltration of sites of injury, may be one helpful diagnostic clue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet sensitive",
"    <span class=\"nowrap\">",
"     enteropathy/arthropathy",
"    </span>",
"    (gluten sensitive enteropathy or celiac disease) may be associated with arthritis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/3\">",
"     3",
"    </a>",
"    ]. Articular involvement was peripheral in 10 percent, axial in 8 percent, and combined in 9 percent. The arthritis is typically nonerosive and can be either oligo-or polyarticular. Joint symptoms may precede gastrointestinal manifestations of the disease. Joint symptoms respond to a gluten free diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient has been described who developed arthritis due to milk allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/36\">",
"     36",
"    </a>",
"    ]. The arthritis could be provoked by challenge with milk and alleviated by milk withdrawal. Occasional patients with lactose deficiency have been reported to have arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Intestinal bypass arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal bypass surgery was developed for the treatment of obesity in 1952; 11 years later arthritis was recognized as a postoperative complication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Polyarthralgia and sometimes arthritis has been reported to occur weeks or years following surgery in 8 to 36 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Because of an unacceptably high incidence of adverse effects, including arthritis, the jejunocolic and jejunoileal bypass operations have been abandoned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Joint pain and tenderness exceed objective findings in most cases of intestinal bypass associated arthropathy, but episodes with abrupt onset of pain and inflammation may also develop. Tenosynovitis is common, with episodes possibly lasting for days and even months affecting the knee, wrist, ankle, shoulder, and finger joints. It may also be responsible for pain in the neck and back. This risk of developing this syndrome is higher after jejunocolic than after jejunoileal surgery and higher in females than males. There is often an associated urticarial, vesicular, pustular, macular, or nodular skin eruption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H27#H27\">",
"     \"Neutrophilic dermatoses\", section on 'Bowel-associated dermatosis-arthritis syndrome'",
"    </a>",
"    .) The Raynaud phenomenon has been reported in one-third of patients.",
"   </p>",
"   <p>",
"    Plain radiographs generally show no joint damage, although marginal erosions may develop in patients with persistent arthritis. Synovial fluids generally have white blood cell counts of 500 to 27,000 per microliter with predominantly polymorphonuclear leukocytes. Synovial biopsies show chronic synovitis with lymphocytes but without lymphoid follicles. Tests for rheumatoid factor, antinuclear antibodies, and HLA-B27 are usually negative, while immune complexes (and cryoglobulins) are often present. These complexes contain bacterial antigens (eg, E. coli, B. fragilis), their antibodies, IgA secretory component, and various complement components (eg, C3, C4, C5) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSAIDs and glucocorticoids are effective in controlling joint symptoms but more lasting results can be achieved by use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    therapy to decrease bacteria overgrowth. Severe and refractory arthritis may require reanastomosis of the bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Parasitic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasitic infections of the gut have been associated with arthritis and other rheumatic disease syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/2,38-40\">",
"     2,38-40",
"    </a>",
"    ]. These include Strongyloides stercoralis, Taenia saginata, Endolimax nana, and Dracunculus medinensis. As the parasites are not isolated from the joints it has been postulated that the joint symptoms represent a form of reactive arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pseudomembranous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis associated with pseudomembranous colitis has been described following antibiotic therapy in case series. In a report of four patients, arthritis developed 9 to 35 days after the onset of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25289/abstract/2\">",
"     2",
"    </a>",
"    ]. The large joints of the lower extremity are most often affected. Clostridium difficile was isolated from two patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=see_link\">",
"       \"Patient information: Reactive arthritis (Reiter syndrome) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=see_link\">",
"       \"Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548492107\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis may occur as an extraintestinal manifestation of several conditions, including inflammatory bowel disease (IBD) and a number of other disorders. Other illnesses, such as Beh&ccedil;et's disease, may cause inflammation of both the joints and the gut. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthritis occurs in a significant minority of patients with IBD, including both ulcerative colitis and regional enteritis (Crohn&rsquo;s disease); it is more likely in patients with large-bowel disease and in those patients with gastrointestinal complications and other extraintestinal involvement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spondylitis more frequently affects men with IBD. Typical symptoms include prolonged stiffness and pain in the back",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      buttocks in the morning or after rest, which is often relieved by exercise. Back symptoms are unrelated to those of the gastrointestinal disease. Limited spinal flexion and reduced chest expansion may occur. Spondylitis may be the only articular manifestation or it may occur in association with type I peripheral arthropathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spondylitis and sacroiliitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type I peripheral arthritis in IBD may be acute, remitting, pauciarticular, and occur early in disease. It commonly involves the knee and is usually nondeforming. Type II peripheral arthritis may be more chronic or have frequent relapses, polyarticular, and frequently involves the metacarpophalangeal joints. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Type I arthropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Type II arthropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute phase reactants usually reflect the activity of the intestinal disease and are not useful in assessing peripheral arthritis or spondylitis. HLA-B27 is found in 50 to 75 percent of the patients with axial arthritis and may be increased in type I peripheral arthritis, but HLA typing has no role in management of individual patients. Synovial fluids are moderately inflammatory. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographs of the spine and pelvis may show typical findings of ankylosing spondylitis and sacroiliitis. Radiographs, particularly of the sacroiliac joints, frequently have abnormal findings even in asymptomatic patients with IBD. Plain radiographs of the peripheral joints may demonstrate soft-tissue swelling, juxtaarticular osteoporosis, mild periostitis, and effusions, usually without erosions or destruction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no pathognomonic finding to confirm that arthritis is due to IBD. It thus remains a diagnosis of exclusion, and septic arthritis should be excluded, particularly in patients with monoarthritis or oligoarthritis, given the risk of fistulization or bacteremia in patients with IBD. The differential diagnosis of arthritis associated with gastrointestinal disease also includes hypertrophic osteoarthropathy, osteonecrosis, erythema nodosum (particularly if periarticular), and the other disorders discussed in this topic review. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective treatment of the underlying IBD is often helpful in controlling the peripheral arthritis of IBD, which is generally nondestructive; therapy is primarily directed at symptomatic relief. In patients with peripheral arthritis we use nonsteroidal antiinflammatory drugs initially, but if these are poorly tolerated use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . If these steps are ineffective we switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine as an alternative. In patients resistant to these therapies we use a tumor necrosis factor (TNF) alpha inhibitor. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Peripheral arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The axial disease associated with IBD is treated similarly to ankylosing spondylitis. The treatment for spinal and sacroiliac involvement is symptomatic and radiographic progression may occur despite the control of symptoms. In patients unresponsive to or intolerant of NSAIDs, we perform a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and if ineffective use a TNF inhibitor. An alternative to methotrexate is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Spondylitis and sacroiliitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other conditions with both intestinal involvement and arthritis as prominent clinical features include reactive arthritis (Reiter syndrome), Whipple's disease, Beh&ccedil;et's disease, celiac disease, parasitic infestation, pseudomembranous colitis, and as a result of intestinal bypass surgery. These disorders are also considerations in the differential diagnosis of patients with suspected IBD and arthritis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other diseases with bowel and joint involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/1\">",
"      Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/2\">",
"      Inman RD. Arthritis and enteritis--an interface of protean manifestations. J Rheumatol 1987; 14:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/3\">",
"      Lubrano E, Ciacci C, Ames PR, et al. The arthritis of coeliac disease: prevalence and pattern in 200 adult patients. Br J Rheumatol 1996; 35:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/4\">",
"      Weiner SR, Clarke J, Taggart N, Utsinger PD. Rheumatic manifestations of inflammatory bowel disease. Semin Arthritis Rheum 1991; 20:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/5\">",
"      Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/6\">",
"      Scarpa R, del Puente A, D'Arienzo A, et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992; 19:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/7\">",
"      Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/8\">",
"      de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/9\">",
"      Tromm A, May D, Almus E, et al. Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001; 39:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/10\">",
"      De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/11\">",
"      Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep 2000; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/12\">",
"      Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/13\">",
"      Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004; 63:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/14\">",
"      Fomberstein B, Yerra N, Pitchumoni CS. Rheumatological complications of GI disorders. Am J Gastroenterol 1996; 91:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/15\">",
"      McEniff N, Eustace S, McCarthy C, et al. Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. Clin Imaging 1995; 19:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/16\">",
"      Kitis G, Thompson H, Allan RN. Finger clubbing in inflammatory bowel disease: its prevalence and pathogenesis. Br Med J 1979; 2:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/17\">",
"      De Keyser F, Van Damme N, De Vos M, et al. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 2000; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/18\">",
"      Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005; 34:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/19\">",
"      Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55 Suppl 1:i36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/20\">",
"      Fornaciari G, Salvarani C, Beltrami M, et al. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001; 15:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/21\">",
"      Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002; 97:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/22\">",
"      Van Bodegraven AA, Pe&ntilde;a AS. Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2003; 6:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/23\">",
"      Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001; 44:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/24\">",
"      Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/25\">",
"      O'Brien J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/26\">",
"      Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/27\">",
"      Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004; 19:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/28\">",
"      Kirsner JB, Shorter RG. Recent developments in \"nonspecific\" inflammatory bowel disease (first of two parts). N Engl J Med 1982; 306:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/29\">",
"      Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/30\">",
"      Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/31\">",
"      Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/32\">",
"      Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/33\">",
"      Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/34\">",
"      De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002; 4:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/35\">",
"      Schiellerup P, Krogfelt KA, Locht H. A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27. J Rheumatol 2008; 35:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/36\">",
"      Panush RS, Stroud RM, Webster EM. Food-induced (allergic) arthritis. Inflammatory arthritis exacerbated by milk. Arthritis Rheum 1986; 29:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/37\">",
"      Ratner D, Schneeyour A, Eshel E, Teitler A. Does milk intolerance affect seronegative arthritis in lactase-deficient women? Isr J Med Sci 1985; 21:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/38\">",
"      McGill PE. Rheumatic syndromes associated with parasites. Baillieres Clin Rheumatol 1995; 9:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/39\">",
"      Peng SL. Rheumatic manifestations of parasitic diseases. Semin Arthritis Rheum 2002; 31:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25289/abstract/40\">",
"      McGill PE. Geographically specific infections and arthritis, including rheumatic syndromes associated with certain fungi and parasites, Brucella species and Mycobacterium leprae. Best Pract Res Clin Rheumatol 2003; 17:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7787 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25289=[""].join("\n");
var outline_f24_44_25289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H548492107\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND ASSOCIATED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ULCERATIVE COLITIS AND CROHN'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Spondylitis and sacroiliitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Type I arthropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Type II arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Peripheral arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Spondylitis and sacroiliitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER DISEASES WITH BOWEL AND JOINT INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Beh&ccedil;et's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intestinal bypass arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Parasitic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pseudomembranous colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H548492107\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7787|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/56/5000\" title=\"diagnostic image 1\">",
"      Sacroiliitis in IBD MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=related_link\">",
"      Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=related_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25290="Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings";
var content_f24_44_25290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Brenna Anderson, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Susan Cu-Uvin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/44/25290/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/44/25290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7448860\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the pregnant woman with HIV infection has evolved significantly over the past 25 years in light of advancements in drug development and a greater understanding of the prevention of perinatal HIV transmission. In the United States and Europe, the risk of HIV transmission from mother to infant had declined to historically low levels with the use of antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Contributions to this successful prevention effort include universal testing of pregnant women for HIV infection, the use of cesarean section (when appropriate) and avoidance of breastfeeding, when feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address the use of antiretroviral medications in the HIV-infected pregnant woman in resource-rich settings. In 2012, the Department of Health and Human Services published updated guidelines on the evaluation and management of HIV-infected pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. Our recommendations below are largely consistent with these guidelines.",
"   </p>",
"   <p>",
"    Information regarding antepartum evaluation and teratogenicity and the pharmacokinetics of individual agents during pregnancy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24037?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Entry and integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information regarding the management of the HIV-infected pregnant female in resource-limited settings and the prevention of HIV transmission through breastfeeding are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448867\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical intervention with antiretroviral (ARV) medications during pregnancy involves two separate but related goals: reduction of perinatal transmission and treatment of maternal HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. It is recommended that all pregnant HIV-infected women receive a combination ARV drug regimen, regardless of CD4 T lymphocyte count or plasma HIV RNA copy number, to prevent perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions about the use of ARV drugs during pregnancy should be made by the woman following discussion with her health care provider of the potential benefits and risks of therapy. Clinicians wishing to discuss management options may consider calling the National Perinatal HIV Consultation and Referral Service at the University of California, San Francisco: 1-888-448-8765.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328729\">",
"    <span class=\"h2\">",
"     Antiretroviral treatment for maternal health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guiding principles of treating HIV infection are no different for the pregnant female than the nonpregnant patient: three-drug combination therapy is used for effective viral suppression and immune recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy should not be a reason to defer standard HIV therapy for maternal health. The main differences in HIV care and management during pregnancy relate to the need for careful drug selection to avoid toxicity in the mother and in the developing fetus. Preferred medications are discussed below. (See",
"    <a class=\"local\" href=\"#H328768\">",
"     'Guide to drug selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328736\">",
"    <span class=\"h2\">",
"     Antiretroviral prophylaxis to prevent perinatal HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal HIV infection can occur during pregnancy, labor and delivery, or during the breastfeeding period. However, with appropriate ARV prophylaxis and effective viral suppression, the risk of an infant becoming infected via perinatal transmission is now estimated to be less than 2 percent in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. Thus, it is recommended that all HIV-infected mothers take antiretroviral prophylaxis, to prevent mother-to-child transmission of HIV, regardless of their CD4 cell count or HIV RNA level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H328983\">",
"     'Data on prevention of HIV perinatal transmission'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women should be educated that use of ARV drugs during pregnancy is highly recommended because viral suppression significantly decreases the risk of transmission to the fetus. However, it is important that clinicians do not create a coercive environment while a woman is weighing the risks and benefits of ARV drug use during decision-making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328935\">",
"    <span class=\"h2\">",
"     Infant antiretroviral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis is also administered to the infant after birth to decrease the risk of HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. Postexposure prophylaxis protects the infant from virus that might have obtained access to the fetal circulation during labor or through exposure to virus during passage through the birth canal.",
"   </p>",
"   <p>",
"    Antiretroviral prophylaxis is particularly important in infants born to women who initiated HIV care and management late in pregnancy. Such women may be at risk of having detectable viremia, even if medication adherence is excellent, since it takes weeks to months for viral suppression to be attained if the patient&rsquo;s baseline viremia was high. Similarly, prophylaxis is critical for the infants of women who were diagnosed with HIV at delivery or otherwise were not taking antepartum ARV drugs. Details of the prophylactic regimens are reviewed below. (See",
"    <a class=\"local\" href=\"#H8627914\">",
"     'Infant prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link&amp;anchor=H22745577#H22745577\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\", section on 'Infant prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the infant whose mother&rsquo;s HIV status is unknown postpartum, rapid HIV antibody testing of the mother or infant is recommended as soon as possible. Infant antiretroviral prophylaxis should be initiated immediately if the rapid test is positive, while awaiting confirmatory HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328751\">",
"    <span class=\"h1\">",
"     HIV VIREMIA AND RISK OF INFANT TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the risk of perinatal transmission declines with low levels of maternal HIV RNA (eg, &lt;1000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    although there is still some element of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective cohort study, HIV RNA levels were serially measured in 1542 HIV-infected women who gave birth from 1990 to 2000 to assess the relationship between plasma viremia, the type of therapeutic intervention, and the risk of HIV perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/1\">",
"     1",
"    </a>",
"    ]. Overall, the number of infant infections declined with increasing complexity of the HIV treatment regimen. HIV transmission rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      20 percent among 396 women who did not receive antiretroviral drugs",
"     </li>",
"     <li>",
"      10 percent for 710 women taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      alone",
"     </li>",
"     <li>",
"      4 percent for 186 women receiving dual antiretroviral drug regimens",
"     </li>",
"     <li>",
"      1 percent for those taking three-drug combination antiretroviral drug regimens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the risk of HIV transmission declined with lower levels of maternal viremia at delivery. HIV transmission rates ranged from 1 percent for patients with a non-detectable viral load (&lt;400",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    compared with 23 percent for those with a viral load &gt;30,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    These data support the use of combination antiretroviral drug regimens with the goal of full viral suppression to decrease the risk of perinatal HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/6\">",
"     6",
"    </a>",
"    ]. These data also highlight the fact that women with a non-detectable viral load can still transmit HIV to their infants, although the risk is low. This residual risk may be related to the presence of detectable HIV in the genital secretions. Thus, antiretroviral prophylaxis is recommended in all pregnant women for the prevention of perinatal transmission, regardless of the mother&rsquo;s viral load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328983\">",
"    <span class=\"h1\">",
"     DATA ON PREVENTION OF HIV PERINATAL TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, AIDS Clinical Trial 076 evaluated the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prophylaxis in preventing perinatal transmission among 477 HIV-infected pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"     7",
"    </a>",
"    ]. Zidovudine was administered during the antepartum and intrapartum period to the mother and in the infant for the first six weeks of life. Women who were randomly assigned to the intervention arm had a significantly lower risk of transmitting HIV infection to their newborn (25 versus 8 percent) with minimal toxic side effects. The infants who received zidovudine had significantly lower hemoglobin levels than those in the placebo arm, but by 12 weeks of life, hemoglobin levels were similar between the two arms.",
"   </p>",
"   <p>",
"    After this landmark trial conducted in the United States and France, many subsequent clinical studies of HIV perinatal transmission have been performed in resource-limited settings to determine if lower-cost medications could be used or if alternative strategies could be as effective. Much of these data are not directly applicable to developed countries due to varying HIV genotypes, patient populations, and infant feeding practices. However, illustrative concepts have emerged from these clinical trials that are also instructive for management of patients in resource-rich settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination regimen is more effective in reducing HIV transmission that a single-drug regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A three-part strategy (ie, antepartum, intrapartum, and infant prophylaxis) is more effective than giving medications only during the intrapartum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postpartum periods [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Starting antiretroviral prophylaxis earlier in pregnancy is more effective in reducing perinatal transmission than starting late in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In a study in South Africa of 730 pregnant women with advanced immune suppression starting antiretroviral drug therapy during pregnancy, each additional week of treatment reduced the odds of perinatal transmission by 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of the clinical trials is available",
"    <a class=\"external\" href=\"file://www.aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/149/lessons-from-international-clinical-trials-of-short-course-antiretroviral-regimens-for-prevention-of-perinatal-transmission-of-hiv\">",
"     online",
"    </a>",
"    through the Department of Health and Human Services (DHHS) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In resource-rich countries, with widespread use of combination antiretroviral regimens during pregnancy, the incidence of perinatal transmission of HIV is estimated at less than 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/2-4,14-16\">",
"     2-4,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328743\">",
"    <span class=\"h1\">",
"     WHEN TO INITIATE ANTIRETROVIRAL MEDICATIONS DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pregnant women who are known to be HIV-infected will already be taking antiretroviral therapy (ART). For pregnant women who are not yet on ART, the rate of virologic control after initiation of a combination antiretroviral regimen appears comparable to that in nonpregnant women. As an example, in a study of 519 antiretroviral na&iuml;ve pregnant women initiating antiretroviral prophylaxis, 93 percent had achieved a HIV viral level &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    by the third month of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/17\">",
"     17",
"    </a>",
"    ]. Available data additionally suggest that earlier initiation of antiretroviral prophylaxis is associated with increased likelihood of viral suppression by the time of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. Some women may prefer delaying antiretroviral prophylaxis until after completion of the first trimester, when the fetus is less susceptible to the potential teratogenic effects of medications. However, later initiation of these agents may be less effective in reducing in utero transmission of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, if antiretroviral prophylaxis is delayed beyond 28 weeks gestation, HIV RNA may not be fully suppressed by the time of delivery, which may increase the risk of perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/11\">",
"     11",
"    </a>",
"    ]. These issues should be discussed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033146\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;If HIV RNA is detectable on the baseline blood test, drug resistance testing should be performed before initiating or modifying antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. However, clinicians need to be aware that drug resistance testing may not be feasible if the viral load is low (eg, &lt;500 to 1000",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiretroviral medications should be initiated while waiting for results of resistance testing if the mother presents late for care (eg, after 28 weeks gestation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328768\">",
"    <span class=\"h1\">",
"     GUIDE TO DRUG SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033004\">",
"    <span class=\"h2\">",
"     Overall approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of combination antiretroviral agents for the treatment of HIV in the nonpregnant patient generally includes a &ldquo;backbone&rdquo; of two",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    reverse transcriptase inhibitors",
"    <span class=\"nowrap\">",
"     (NRTIs/NtRTIs)",
"    </span>",
"    plus a third agent from either the protease inhibitor (PI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or integrase inhibitor drug classes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar approach is taken in the pregnant HIV-infected woman receiving three-drug antiretroviral regimens for either HIV treatment or for the prevention of mother-to-child transmission (MTCT) of HIV, with some important exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      is no longer considered a preferred agent for the treatment of HIV infection in the nonpregnant patient, zidovudine is considered a first-line medication during pregnancy because of its demonstrated efficacy in decreasing MTCT of HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      is a first-line NNRTI for treatment-naive patients, initiation of this agent during the first trimester is not recommended due to the potential risk of teratogenicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"       \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"       \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      should not routinely be initiated in treatment-na&iuml;ve women with CD4 cell counts &gt;250 cells",
"      <span class=\"nowrap\">",
"       /mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      because of potential hepatotoxicity and fatal rash.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, regimen selection should be based on safety and efficacy of the drugs in the mother and fetus, convenience, adherence potential, tolerability, potential for drug interactions with other medications, pharmacokinetic data in pregnancy, and the resistance profile of the virus. The medications to continue in treatment-eligible pregnant women who are already receiving therapy have not been evaluated systematically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/19\">",
"     19",
"    </a>",
"    ]. Also the long-term virologic and immunologic efficacy of antiretroviral drugs in the HIV-infected pregnant woman has not been evaluated in randomized clinical trials and few comparative data are available on the most efficacious agents to use. Most of the available data on antiretroviral drugs are focused on the safety and efficacy of antiretroviral medications in preventing infant transmission, as opposed to the efficacy of these drugs for the treatment of HIV in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following information discusses preferred agents within each drug class for use in pregnant women; the use of combination regimens in treatment-naive and treatment-experienced patients is discussed below. (See",
"    <a class=\"local\" href=\"#H7448874\">",
"     'Combination antiretroviral drug regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328796\">",
"    <span class=\"h2\">",
"     Preferred nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, clinical trial data clearly demonstrate the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) in reducing the risk of perinatal HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"     7",
"    </a>",
"    ]. ZDV also rapidly crosses the placenta providing protective serum levels of drug in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/20\">",
"     20",
"    </a>",
"    ]. ZDV, combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , is the preferred NRTI in combination regimens in pregnancy because of its documented efficacy in preventing HIV transmission to infants and its ability to cross the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. It should be used in all pregnant women unless there is a known history of severe toxicity, documented drug resistance, or the woman is already on a fully suppressive drug regimen. Due to its safety profile, lamivudine (3TC) is the preferred drug to be used in combination with ZDV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. For patient convenience, both drugs are usually given as the co-formulation Combivir as one pill given twice daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative",
"    <span class=\"nowrap\">",
"     NRTI/NNRTIs",
"    </span>",
"    with good placental passage such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    should be considered if there is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    toxicity such as anemia.",
"   </p>",
"   <p>",
"    For pregnant women with HIV and hepatitis B coinfection,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is the preferred NRTI backbone in a combination regimen. Although animal studies have suggested the potential for decreased fetal growth and reduction in fetal bone porosity with tenofovir exposure, evaluations in human infants with tenofovir exposure have been reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. However, there are only limited data at the current",
"    <span class=\"nowrap\">",
"     time.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328836\">",
"    <span class=\"h2\">",
"     Preferred protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir/",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is the preferred PI for antiretroviral (ARV)-na&iuml;ve pregnant women because of efficacy studies in adults and experience with its use in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. No increased risk of teratogenicity has been reported in the Antiretroviral Pregnancy Registry among pregnant women exposed to",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    in the first trimester (1.7 versus 2.7 percent in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/21\">",
"     21",
"    </a>",
"    ]. Combination regimens containing",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    have been shown to significantly decrease the risk of mother-to-child transmission of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. Several studies have shown decreased lopinavir plasma concentrations with standard dosing during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One pharmacokinetic study in 33 women evaluated 600 mg lopinavir with 150 mg ritonavir twice daily during the third trimester and demonstrated that serum levels were similar to those seen in nonpregnant adults taking standard dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, some experts recommend that",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    dosing should be increased to 600",
"    <span class=\"nowrap\">",
"     mg/150",
"    </span>",
"    mg twice a day in the third trimester in treatment-experienced women and standard dosing be used for antiretroviral-naive women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Once-daily dosing should be avoided during pregnancy due to concerns regarding insufficient serum trough levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link&amp;anchor=H32#H32\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\", section on 'Lopinavir-ritonavir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is also a preferred PI for ARV-na&iuml;ve pregnant women. Several studies have shown decreased ATV plasma concentrations with standard dosing during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Use of an increased dose during the second and third trimesters resulted in plasma concentrations equivalent to those in nonpregnant adults on standard dosing. Although some experts recommend increased ATV dosing in all women during the second and third trimesters, the package insert recommends increased ATV dosing only for ARV-experienced pregnant women in the second and third trimesters also receiving either TDF or an H",
"    <sub>",
"     2",
"    </sub>",
"    -receptor antagonist or ARV-naive pregnant women receiving EFV. ATV should not be used in patients receiving both TDF and H",
"    <sub>",
"     2",
"    </sub>",
"    receptor antagonists or in ARV-experienced patients also taking EFV.",
"   </p>",
"   <p>",
"    Alternative PIs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , although experience with these regimens in pregnancy is more limited.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    has a favorable pharmacokinetic and safety profile in pregnant women; however, nelfinavir is no longer a preferred agent because of its lower overall virologic efficacy. Nelfinavir might be considered in special circumstances when used solely for prophylaxis of MTCT in antiretroviral-na&iuml;ve women or when alternative agents are not tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329145\">",
"    <span class=\"h2\">",
"     Preferred non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI) in women with a CD4 cell count &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is not recommended in women with CD4 cell counts &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    because of increased risk of potential fatal rash and hepatotoxicity. However, in an antiretroviral-experienced woman already receiving nevirapine as part of an effective treatment regimen, it can be continued regardless of CD4 count. (See",
"    <a class=\"local\" href=\"#H2033094\">",
"     'Special considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is a first-line NNRTI for treatment-naive patients, it is generally not recommended for initiation of antiretroviral regimens in antiretroviral-na&iuml;ve women during the first trimester due to the potential risk of teratogenicity. Use of efavirenz may be considered after the first trimester, as appropriate. (See",
"    <a class=\"local\" href=\"#H2033094\">",
"     'Special considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448874\">",
"    <span class=\"h1\">",
"     COMBINATION ANTIRETROVIRAL DRUG REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;How and when to start antiretroviral drug regimens during pregnancy is the topic of guidelines produced by the US Department of Health and Human Services and is updated regularly. These guidelines can be accessed at",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\">",
"     file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf",
"    </a>",
"    . In the United States, the National Perinatal HIV hotline can also be accessed at 1-888-448-8765.",
"   </p>",
"   <p>",
"    The following synopsis outlines the major considerations for constructing an antiretroviral regimen for the pregnant HIV-infected patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448881\">",
"    <span class=\"h2\">",
"     Treatment-na&iuml;ve patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448889\">",
"    <span class=\"h3\">",
"     Recommended regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the treatment-naive HIV-infected pregnant female, the following regimen is preferred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"        atazanavir",
"       </a>",
"       /ritonavir",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in a treatment-na&iuml;ve HIV-infected pregnant woman with hepatitis B coinfection, the following regimen is preferred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"        atazanavir",
"       </a>",
"       /ritonavir",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033404\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who cannot tolerate",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"      atazanavir",
"     </a>",
"     /ritonavir",
"    </span>",
"    and are taking antiretroviral medications solely for prophylaxis may be considered for an alternative regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      (if the CD4 cell count &lt;250",
"      <span class=\"nowrap\">",
"       cells/mL)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"     </li>",
"     <li>",
"      Alternative",
"      <span class=\"nowrap\">",
"       NRTI/NNRTIs",
"      </span>",
"      with good placental passage such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      should be considered if there is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      toxicity such as anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448903\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448911\">",
"    <span class=\"h3\">",
"     Women not on antiretroviral drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to obtain a history of all prior antiretroviral drug exposure and results of prior resistance testing (if done previously) in women who have a history of antiretroviral exposure in the past. Drug resistance testing should be used to guide the choice of combination drug regimen.",
"   </p>",
"   <p>",
"    The virologic response must be monitored carefully. Women who do not show an appropriate virologic response require a repeat resistance panel test. They should also have a consultation with a clinician experienced in antiretroviral drug resistance. The recommended next-line therapy will vary based on the individual patient&rsquo;s prior exposure and drug resistance profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448918\">",
"    <span class=\"h3\">",
"     Women with viral suppression on antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have achieved viral suppression on antiretroviral drugs before pregnancy can continue their current regimen during pregnancy.",
"   </p>",
"   <p>",
"    Exceptions to this include the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , which should be avoided. (See",
"    <a class=\"local\" href=\"#H2033094\">",
"     'Special considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although there is a possible risk of neural tube defects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , the risk of such defects is restricted to the first five to six weeks of pregnancy. Because pregnancy is frequently not recognized this early and unnecessary antiretroviral drug changes during pregnancy may be associated with loss of viral control and increased risk of perinatal transmission, women who become pregnant while receiving efavirenz can continue their regimen provided there is virologic suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/32\">",
"     32",
"    </a>",
"    ]. In such situations, additional fetal monitoring (eg, second trimester ultrasound) should be considered to evaluate fetal anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link&amp;anchor=H5#H5\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\", section on 'Efavirenz'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    use is considered safe if the patient has a documented history of viral suppression; in this scenario, nevirapine can be continued, regardless of CD4 cell count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448925\">",
"    <span class=\"h3\">",
"     Women on antiretroviral therapy without viral suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women receiving antiretroviral therapy prior to pregnancy may sometimes become pregnant at a time when full viral suppression has not been achieved. In this case, the clinician must begin by asking the patient about their level of drug adherence. Nonadherence can allow for incomplete viral suppression merely due to the lack of adequate drug level.",
"   </p>",
"   <p>",
"    Drug resistance testing is also recommended in this situation and antiretroviral drug regimens should be tailored to the individual woman based on her resistance profile and individual medication tolerability. Consultation with an HIV expert is recommended. Adherence may improve with provision of support services, mental health care, and public assistance programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3332937\">",
"    <span class=\"h1\">",
"     PREGNANCY COMPLICATIONS AND OUTCOMES WITH ANTIRETROVIRAL USE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347793514\">",
"    <span class=\"h2\">",
"     Gestational diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although protease inhibitors are associated with insulin resistance and impaired glucose tolerance in general, most studies in pregnant woman do not indicate an increased rate of gestational diabetes with their use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In a multicenter prospective study of HIV-infected pregnant women in the US, there was no difference between the 76 women taking and the 73 not taking a protease inhibitor in the incidence of abnormal glucose tolerance following oral glucose challenge (33 versus 26 percent), gestational diabetes (8 versus 10 percent), and macrosomia &gt;4 kg (5 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/33\">",
"     33",
"    </a>",
"    ]. The rate of glucose intolerance and gestational diabetes in this study was higher than historically reported in the general population, possibly because of the relatively high body mass index in both groups. However, this may also reflect the finding that use of ART of any kind may increase the risk of gestational diabetes in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/36\">",
"     36",
"    </a>",
"    ]. HIV-infected pregnant women on combination antiretroviral therapy should undergo glucose screening consistent with standard pregnancy recommendations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link&amp;anchor=H15#H15\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\", section on 'How to screen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3332952\">",
"    <span class=\"h2\">",
"     Small for gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the risk of combination antiretroviral agents during pregnancy on poor fetal growth and low birth weight have demonstrated conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. Whether poor growth is due to underlying maternal characteristics or due to the medications themselves, some assessment of fetal growth is important in HIV-infected pregnancies. While some experts would rely on appropriate growth of uterine fundal height, others recommend ultrasound assessment in the third trimester to ensure adequate fetal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link&amp;anchor=H86989366#H86989366\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\", section on 'Prenatal fetal monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3332959\">",
"    <span class=\"h2\">",
"     Preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a possible small increased risk of preterm delivery prior to 37 weeks gestation with combination antiretroviral regimens, particularly with those that contain protease inhibitors, although the data from prospective cohort studies are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/4,43-49\">",
"     4,43-49",
"    </a>",
"    ]. Even in those studies that demonstrate an increased risk with protease inhibitors, the increases are modest, and the effects on neonatal morbidity and mortality are unknown. Thus, given the clear benefits to maternal health and a reduction in perinatal transmission of HIV, a protease inhibitor-based combination antiretroviral regimen remains the recommendation for HIV-infected pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033094\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033306\">",
"    <span class=\"h2\">",
"     Nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the nucleoside reverse transcriptase inhibitors, there are concerns regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , which are briefly described below. The use of nucleoside reverse transcriptase inhibitors is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033313\">",
"    <span class=\"h3\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies have shown decreased fetal growth and reduction in fetal bone porosity and studies in children show bone demineralization with chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    administration. Thus, although tenofovir is a preferred NRTI for use in nonpregnant adults, it is considered an alternative NRTI during pregnancy for antiretroviral-na&iuml;ve women who do not have hepatitis B coinfection. Data from the Antiretroviral Pregnancy Registry on 1219 pregnancies with first trimester exposure to tenofovir have not indicated an increase in birth defects compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/21\">",
"     21",
"    </a>",
"    ]. Studies evaluating the longer-term effects of intrauterine tenofovir exposure on infant growth have demonstrated conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link&amp;anchor=H50#H50\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\", section on 'Human studies in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    all have dual activity against HIV and hepatitis B virus infections. For pregnant women with chronic hepatitis B infection, tenofovir in combination with lamivudine or emtricitabine are the preferred NRTIs to use as part of a combination antiretroviral medication regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033320\">",
"    <span class=\"h3\">",
"     Stavudine and didanosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have high affinity for mitochondrial gamma DNA polymerase and subsequently lead to mitochondrial toxicity more commonly than other nucleoside reverse transcriptase inhibitors. Due to the concern for lactic acidosis and fatal hepatic failure, the combination of stavudine (D4T) and didanosine (DDI) should be avoided in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033231\">",
"    <span class=\"h2\">",
"     Nonnucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caveats regarding the use of nonnucleoside reverse transcriptase inhibitors are discussed briefly here. The use of nonnucleoside reverse transcriptase inhibitors during pregnancy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033166\">",
"    <span class=\"h3\">",
"     Efavirenz",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI) for treatment-naive patients, it is not recommended during the first trimester due to the potential risk of teratogenicity. Neural tube defects, facial clefts, and anophthalmia have been reported in primate models as well as in some retrospective human subject data. While prospective data collection has not confirmed an increased risk of fetal anomalies with the use of efavirenz in pregnancy, the number of reported first-trimester efavirenz exposures still remains insufficient to rule out a significant increase in low-incidence birth defects (incidence of neural tube defects in the general US population is 0.02 to 0.2 percent). Furthermore, the consistent nature of the anomalies in the primates and retrospective human cases has led to recommendations to avoid its initiation during the first trimester in pregnant women, women planning to become pregnant, or women of childbearing age who do not use reliable contraception.",
"   </p>",
"   <p>",
"    If women are found to be in the first trimester of pregnancy while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , the risk of loss of virological control and subsequent possible perinatal transmission with antiretroviral switching may outweigh the risk of possible teratogenicity, particularly since many pregnancies are recognized after the window of risk for neural tube defects (the first five to six weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/32\">",
"     32",
"    </a>",
"    ]. Such women can continue an efavirenz-based regimen, with appropriate fetal monitoring (eg, second trimester ultrasound) to evaluate fetal anatomy. Use of efavirenz in later gestation can be considered if there are not better alternatives for a specific woman. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link&amp;anchor=H5#H5\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\", section on 'Efavirenz'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033192\">",
"    <span class=\"h3\">",
"     Nevirapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    should not routinely be initiated in women with a CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    because of an increased risk of hypersensitivity syndrome characterized by rash and hepatotoxicity, which can be fatal.",
"   </p>",
"   <p>",
"    However, women who are already receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    as part of a fully suppressive regimen should continue on that regimen, regardless of their CD4 count, since the risk of toxicity is low when HIV RNA is not detectable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15623826\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15623833\">",
"    <span class=\"h3\">",
"     Indinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dosing regimen for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    in pregnancy is not known. Therefore it is rarely used in pregnancy. When used, it should be boosted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    and consideration should be given to following both serial viral loads as well as trough drug levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9783061\">",
"    <span class=\"h2\">",
"     Integrase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9783069\">",
"    <span class=\"h3\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the integrase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    during pregnancy are limited but increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/50\">",
"     50",
"    </a>",
"    ]; therefore, treatment regimens including raltegravir can be considered for use in pregnancy in special circumstances when preferred and alternative agents cannot be used. Anecdotally, raltegravir has been used in late pregnancy among women with high viral loads because of its ability to rapidly decrease viral load within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. The efficacy and safety of this has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2033353\">",
"    <span class=\"h1\">",
"     DRUGS WITH INSUFFICIENT DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many medications in the HIV armamentarium that have not been well evaluated in the pregnant patient. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    , etravirine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    . Occasionally such agents may be needed if the patient has significant drug resistance. The risks and benefits of such an approach need to be conveyed to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8630301\">",
"    <span class=\"h1\">",
"     INTRAPARTUM ANTIRETROVIRALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should continue taking their combination antiretroviral regimen as much as possible during labor and delivery or scheduled cesarean section. Additional administration of intrapartum intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) depends on the maternal HIV viral load near the time of delivery.",
"   </p>",
"   <p>",
"    ZDV crosses the placenta rapidly and can provide pre-exposure prophylaxis to the fetus. In the PACTG 076 trial, combined antepartum ZDV, intravenous ZDV during labor, and six weeks of infant ZDV prophylaxis reduced perinatal transmission by 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"     7",
"    </a>",
"    ]. There are no randomized clinical trials evaluating the benefit of intravenous ZDV during labor among women using current combination ARV regimens. However, among 2845 women from the French Perinatal Cohort who had HIV RNA &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at delivery, receipt of intravenous ZDV intrapartum was not associated with a decreased risk of mother-to-child HIV transmission (transmission rates of 0.6 percent [17 of 2750] and 0 percent [0 of 95] with and without intrapartum ZDV, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, intravenous ZDV is no longer recommended for HIV-infected women on combination ARV with HIV RNA &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    near the time of delivery. However, intravenous ZDV continues to be recommended for women with HIV RNA &gt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    near delivery or unknown HIV RNA levels. For women scheduled for cesarean section with HIV RNA &gt;400",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    intravenous ZDV should be given three hours before cesarean section. HIV-infected women who present in labor and have not taken any ARV medications should be given intravenous ZDV immediately to prevent perinatal transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9782365\">",
"    <span class=\"h1\">",
"     POSTPARTUM CONTINUATION OF ANTIRETROVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations regarding continuation of antiretroviral (ARV) agents in the postpartum period are similar to those for nonpregnant individuals in terms of risks and benefits of therapy at a given CD4 count. Data from randomized controlled trials and observational studies demonstrate clinical benefits to personal health with ARV treatment in adults with a CD4 cell count &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    For adults with higher CD4 cell counts, the data are more limited but also suggestive of decreased morbidity with ARV agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H2622983#H2622983\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'The clinical benefit of ART varies by baseline CD4 cell count'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, among women with a CD4 cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    the potential benefits of early therapy must be weighed against their willingness to continue therapy, possible drug toxicity, cost, and the risk of development of viral resistance with suboptimal adherence. In the postpartum period, adherence to an antiretroviral regimen may be particularly difficult. In a meta-analysis of studies of ARV use during and after pregnancy, the pooled rate of adequate adherence (&gt;80 percent of doses) in the postpartum setting was only 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/57\">",
"     57",
"    </a>",
"    ]. This finding highlights the importance of careful adherence counseling and social support during the postpartum period in an effort to mitigate the risk of poor compliance among those who continue an ARV regimen.",
"   </p>",
"   <p>",
"    The effect on long-term maternal health of postpartum discontinuation of combination ARV drug regimens used solely to prevent perinatal transmission is unknown. Furthermore, some women may have multiple pregnancies resulting in episodic use of ARV drugs. Thus far, a significant increase in disease progression after stopping antiretroviral prophylaxis postpartum has not been shown in women with higher CD4 count [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. A multicenter trial evaluating the risks and benefits of stopping ARV drug regimens in postpartum women with high CD4 cell counts is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8627914\">",
"    <span class=\"h1\">",
"     INFANT PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that all infants born to HIV-positive mothers receive postexposure prophylaxis after birth to decrease the risk of HIV acquisition. Such infants should receive six weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV), appropriately dosed for gestational age at birth (",
"    <a class=\"graphic graphic_table graphicRef85990 \" href=\"UTD.htm?38/48/39692\">",
"     table 1",
"    </a>",
"    ) and ideally initiated within 6 to 12 hours of delivery. Further infant antiretroviral (ARV) prophylaxis depends on the prenatal care and HIV disease status of the mother.",
"   </p>",
"   <p>",
"    In the landmark ACTG 076 trial of ZDV for prevention of mother-to-child HIV transmission, ZDV was given to HIV-infected pregnant women antepartum and during labor and to infants for six weeks as postexposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"     7",
"    </a>",
"    ]. HIV transmission was reduced by 66 percent among infants in the ZDV group (8.3 versus 25.5 percent of infants infected with placebo). Although a combination regimen is now preferred for prenatal ARV therapy of the HIV-infected pregnant woman, the administration of ZDV to the infant for six weeks remains the standard of care for all HIV-exposed infants.",
"   </p>",
"   <p>",
"    In some situations, no maternal antepartum ARV drugs have been given (eg, women first diagnosed with HIV during labor), and only infant ARV prophylaxis with or without maternal intrapartum prophylaxis can be provided. Such infants should be given six weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prophylaxis combined with three doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    in the first week of life (at birth, 48 hours later, and 96 hours after the second dose). This recommendation is supported by the findings of the HIV Prevention Trials Network (HPTN)",
"    <span class=\"nowrap\">",
"     040/Pediatric",
"    </span>",
"    AIDS Clinical Trial Group 1043 study, which compared the efficacy of three infant prophylaxis regimens in preventing mother-to-child transmission of HIV for pregnant women who presented late to care and received only intrapartum ZDV or no ARV agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/62\">",
"     62",
"    </a>",
"    ]. About one quarter of women in all three groups received cesarean section prior to the rupture of membranes. The rate of intrapartum transmission of HIV was higher when infants received six weeks of ZDV alone (4.8 percent) than when they received ZDV plus three doses of nevirapine over eight days (2.2 percent) or ZDV plus two weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (2.4 percent). In addition to prophylaxis with ZDV alone, high maternal viral load and maternal use of illegal substances were independently associated with transmission. Serious adverse effects, including neutropenia, were more common with the triple drug regimen than the other two. Thus, the zidovudine plus nevirapine regimen offers the most favorable balance between efficacy and side effects.",
"   </p>",
"   <p>",
"    Infants of women who have received antepartum ARV drugs but have detectable viremia (HIV RNA &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    near the time of delivery should be delivered by scheduled cesarean. These infants should receive at least prophylactic ZDV for six weeks. There are no studies evaluating whether administration of other ARV agents to the infant in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    confers further benefit in reducing HIV transmission risk in this setting. However, when maternal viral load is high near the time of delivery, and particularly when HIV RNA exceeds 1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in women who deliver vaginally, infant prophylaxis with zidovudine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    should be considered based on extrapolation of the data from the HPTN 040 trial above. The decision should be made in consultation with HIV specialists, if available.",
"   </p>",
"   <p>",
"    For the infant whose mother&rsquo;s HIV status is unknown postpartum, rapid HIV antibody testing of the mother or infant is recommended as soon as possible. Infant antiretroviral prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    should be initiated immediately if the rapid test is positive, while awaiting confirmatory HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that pharmacokinetic data to allow appropriate dosing recommendations in neonates are available only for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , and in preterm infants, only for zidovudine and nevirapine. The use of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    in four preterm infants (two sets of twins) was associated with heart block that resolved after discontinuation of the drugs; thus, this drug is not recommended for use in neonates for prophylaxis of mother-to-child transmission of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/44/25290/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328952\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States and Europe, the risk of HIV transmission from mother to infant has declined to historically low levels with the use of antiretroviral (ARV) medications. (See",
"      <a class=\"local\" href=\"#H7448860\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical intervention with ARV medications during pregnancy involves two separate but related goals: reduction of perinatal transmission and treatment of maternal HIV disease. All HIV-infected pregnant women should be offered ARV medications to prevent mother-to-child transmission (MTCT) of HIV infection. ARV prophylaxis consists of a three-drug combination regimen with the ultimate goal of complete viral suppression. (See",
"      <a class=\"local\" href=\"#H7448867\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H328751\">",
"       'HIV viremia and risk of infant transmission'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H328983\">",
"       'Data on prevention of HIV perinatal transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Earlier initiation of an ARV regimen is associated with increased likelihood of viral suppression by the time of delivery and thus decreased risk of transmission but must be weighed against potential teratogenic effects of medications. (See",
"      <a class=\"local\" href=\"#H328743\">",
"       'When to initiate antiretroviral medications during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women, ARV drug selection should be guided by the individual drug safety profile during pregnancy, ability to cross the placenta, and overall efficacy in achieving viral suppression. (See",
"      <a class=\"local\" href=\"#H2033004\">",
"       'Overall approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the treatment-naive HIV-infected pregnant woman, the preferred regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"        atazanavir",
"       </a>",
"       /ritonavir.",
"      </span>",
"      For those women who also have hepatitis B virus infection,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      should replace zidovudine in the regimen. (See",
"      <a class=\"local\" href=\"#H7448881\">",
"       'Treatment-na&iuml;ve patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In treatment-experienced women, it is important to obtain a history of all prior ARV drug exposure and results of previous resistance testing. Drug resistance testing should be used to guide the choice of combination ARV regimen. Women who have achieved viral suppression on an ARV regimen before pregnancy can continue their current regimen during pregnancy unless it includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7448903\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There may be a small increased risk of preterm delivery and impaired fetal growth with the use of ARV agents, particularly protease inhibitors during pregnancy, but the data from studies are conflicting. (See",
"      <a class=\"local\" href=\"#H3332937\">",
"       'Pregnancy complications and outcomes with antiretroviral use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should continue taking their combination ARV regimen during labor and delivery or scheduled cesarean section. Intravenous intrapartum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      should be administered to women with HIV RNA &gt;400",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      or with unknown levels, but it is not recommended for women on a combination ARV regimen with a known viral load below that threshold. (See",
"      <a class=\"local\" href=\"#H8630301\">",
"       'Intrapartum antiretrovirals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Considerations regarding continuation of ARV agents in the postpartum period are similar to those for nonpregnant individuals in terms of risks and benefits of therapy at a given CD4 count. All patients who continue ARV agents postpartum should be counselled on the importance of strict adherence to their regimen. (See",
"      <a class=\"local\" href=\"#H9782365\">",
"       'Postpartum continuation of antiretroviral agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All infants born to HIV-infected mothers should receive at least six weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      prophylaxis after birth to decrease the risk of HIV acquisition. The indication for additional ARV prophylaxis depends on the mother&rsquo;s use of antepartum ARV agents (",
"      <a class=\"graphic graphic_table graphicRef85990 \" href=\"UTD.htm?38/48/39692\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8627914\">",
"       'Infant prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/1\">",
"      Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/2\">",
"      Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, July 31, 2012. file://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/ (Accessed on August 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/4\">",
"      Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 157:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/5\">",
"      Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads &lt;1000 copies/ml. J Infect Dis 2001; 183:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/6\">",
"      Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; :CD003510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/7\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/8\">",
"      Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/9\">",
"      Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/10\">",
"      Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/11\">",
"      Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/12\">",
"      Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2010; 54:35.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=9 (Accessed on December 17, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/14\">",
"      Forbes JC, Alimenti AM, Singer J, et al. A national review of vertical HIV transmission. AIDS 2012; 26:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/15\">",
"      European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/16\">",
"      Peters VB, Liu KL, Robinson LG, et al. Trends in perinatal HIV prevention in New York City, 1994-2003. Am J Public Health 2008; 98:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/17\">",
"      Rachas A, Warszawski J, Le Chenadec J, et al. Does pregnancy affect the early response to cART? AIDS 2013; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/18\">",
"      Read PJ, Mandalia S, Khan P, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/19\">",
"      Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010; :CD008440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/20\">",
"      Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001; 41:732.",
"     </a>",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 &ndash; 1 Jan 2010. Wilmington, NC: Registry coordinating center; 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/22\">",
"      Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/23\">",
"      Vigan&ograve; A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/24\">",
"      Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/25\">",
"      Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/26\">",
"      Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/27\">",
"      Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/28\">",
"      Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010; 24:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/29\">",
"      Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/30\">",
"      Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409.",
"     </a>",
"    </li>",
"    <li>",
"     Eley T, Child M, Wang Y, et al. The steady state pharmacokinetics (PK) of atazanavir/ritonavir (ATV/RTV) during pregnancy in HIV+ women. Paper presented at: 47th Infectious Diseases Society of America; October 29-November 1, 2009; Philadelphia, PA",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/32\">",
"      Floridia M, Ravizza M, Pinnetti C, et al. Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clin Trials 2010; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/33\">",
"      Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/34\">",
"      Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/35\">",
"      Watts DH, Balasubramanian R, Maupin RT Jr, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/36\">",
"      Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/37\">",
"      Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2007; 119:e900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/38\">",
"      Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009; 23:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/39\">",
"      Floridia M, Ravizza M, Bucceri A, et al. Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIV. HIV Clin Trials 2008; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/40\">",
"      Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/41\">",
"      Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/42\">",
"      Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/43\">",
"      Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/44\">",
"      Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 2010; 117:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/45\">",
"      Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/46\">",
"      Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med 2011; 12:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/47\">",
"      Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/48\">",
"      Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/49\">",
"      Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/50\">",
"      Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS 2011; 22:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/51\">",
"      Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/52\">",
"      Papendorp SG, van den Berk GE. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load. AIDS 2009; 23:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/53\">",
"      McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010; 24:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/54\">",
"      Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010; 65:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/55\">",
"      Westling K, Pettersson K, Kaldma A, Nav&eacute;r L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS 2012; 26:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/56\">",
"      Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/57\">",
"      Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/58\">",
"      Watts DH, Lu M, Thompson B, et al. Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009; 2009:456717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/59\">",
"      Palacios R, Senise J, Vaz M, et al. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers. HIV Med 2009; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/60\">",
"      Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007; 196:1044.",
"     </a>",
"    </li>",
"    <li>",
"     Examining Benefits of HAART Continuation in Postpartum Mothers. file://www.clinicaltrials.gov/ct2/show/NCT00955968 (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/62\">",
"      Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/44/25290/abstract/63\">",
"      McArthur MA, Kalu SU, Foulks AR, et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 2009; 28:1127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15799 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25290=[""].join("\n");
var outline_f24_44_25290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H328952\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448860\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448867\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328729\">",
"      Antiretroviral treatment for maternal health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328736\">",
"      Antiretroviral prophylaxis to prevent perinatal HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328935\">",
"      Infant antiretroviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328751\">",
"      HIV VIREMIA AND RISK OF INFANT TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328983\">",
"      DATA ON PREVENTION OF HIV PERINATAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328743\">",
"      WHEN TO INITIATE ANTIRETROVIRAL MEDICATIONS DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2033146\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328768\">",
"      GUIDE TO DRUG SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2033004\">",
"      Overall approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328796\">",
"      Preferred nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328836\">",
"      Preferred protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H329145\">",
"      Preferred non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448874\">",
"      COMBINATION ANTIRETROVIRAL DRUG REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7448881\">",
"      Treatment-na&iuml;ve patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7448889\">",
"      - Recommended regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2033404\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7448903\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7448911\">",
"      - Women not on antiretroviral drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7448918\">",
"      - Women with viral suppression on antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7448925\">",
"      - Women on antiretroviral therapy without viral suppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3332937\">",
"      PREGNANCY COMPLICATIONS AND OUTCOMES WITH ANTIRETROVIRAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347793514\">",
"      Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3332952\">",
"      Small for gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3332959\">",
"      Preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2033094\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2033306\">",
"      Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2033313\">",
"      - Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2033320\">",
"      - Stavudine and didanosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2033231\">",
"      Nonnucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2033166\">",
"      - Efavirenz",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2033192\">",
"      - Nevirapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15623826\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15623833\">",
"      - Indinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9783061\">",
"      Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9783069\">",
"      - Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2033353\">",
"      DRUGS WITH INSUFFICIENT DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8630301\">",
"      INTRAPARTUM ANTIRETROVIRALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9782365\">",
"      POSTPARTUM CONTINUATION OF ANTIRETROVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8627914\">",
"      INFANT PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328952\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/48/39692\" title=\"table 1\">",
"      Infant HIV prophylaxis regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24037?source=related_link\">",
"      Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=related_link\">",
"      Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=related_link\">",
"      Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=related_link\">",
"      Antiretroviral medications in pregnancy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27994?source=related_link\">",
"      Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_44_25291="Causes of enterocutaneous fistulae";
var content_f24_44_25291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of enterocutaneous fistulae",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postoperative",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn disease",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diverticular disease",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other*",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * \"Other\" includes rare conditions such as enteric vasculitis or myopathy or no associated condition.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25291=[""].join("\n");
var outline_f24_44_25291=null;
var title_f24_44_25292="Wrist examination";
var content_f24_44_25292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examination of the wrist",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain and stiffness at full wrist flexion or extension or both*",
"       </td>",
"       <td rowspan=\"3\">",
"        #1 - Wrist sprain",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Wrist series x-ray is normal",
"        </p>",
"        <p>",
"         Resolves in two weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal dorsal swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal tenderness over the navicular and lunate bones",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Loss of full wrist flexion and full wrist extension*",
"       </td>",
"       <td rowspan=\"2\">",
"        Radiocarpal arthritis",
"       </td>",
"       <td rowspan=\"2\">",
"        Wrist series x-ray or local anesthetic block in the radiocarpal joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal swelling and tenderness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Loss of full wrist flexion and full wrist extension*",
"       </td>",
"       <td rowspan=\"3\">",
"        Navicular fracture",
"       </td>",
"       <td rowspan=\"3\">",
"        Wrist series x-ray or bone scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal swelling and tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Point tenderness over the navicular or lunate dorsally or the snuff box",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cystic swelling over the dorsum of the wrist*",
"       </td>",
"       <td>",
"        Dorsal ganglion",
"       </td>",
"       <td>",
"        Simple aspiration of gelatinous fluid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dysesthesias or paresthesias by history*",
"       </td>",
"       <td rowspan=\"2\">",
"        Carpal tunnel syndrome",
"       </td>",
"       <td rowspan=\"2\">",
"        Medial nerve block with anesthesia or nerve conduction studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tinel or Phalen sign",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Point tenderness over the lateral wrist just distal to the ulnar styloid*",
"       </td>",
"       <td rowspan=\"2\">",
"        Triangular cartilage injury",
"       </td>",
"       <td rowspan=\"2\">",
"        MRI of the wrist or anesthetic block in the ulnar-radial joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain with forced ulnar deviation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pain with resisted finger extension*",
"       </td>",
"       <td rowspan=\"2\">",
"        Dorsal tenosynovitis",
"       </td>",
"       <td rowspan=\"2\">",
"        Anesthetic block of the tenosynovial sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse swelling over the dorsum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *: Is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"     <br>",
"      #1: Refers to the most common condition affecting the wrist.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25292=[""].join("\n");
var outline_f24_44_25292=null;
var title_f24_44_25293="Bacterial tracheitis Rx";
var content_f24_44_25293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested intravenous antimicrobial treatment regimens for bacterial tracheitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       For patients without hypersensitivity to penicillin or cephalosporin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Vancomycin*&bull;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       40 to 60 mg/kg per day in three to four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 4 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Clindamycin",
"      </td>",
"      <td>",
"       40 mg/kg per day in three divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 2.7 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       <strong>",
"        <span class=\"red\">",
"         PLUS",
"        </span>",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Ceftriaxone&Delta;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       50 to 100 mg/kg per day once daily or in two divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 2 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Cefotaxime&bull;&Delta;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       150 to 200 mg/kg per day in four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 10 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Ampicillin-sulbactam&bull;",
"      </td>",
"      <td>",
"       150 to 200 mg/kg (of ampicillin component) per day in four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 8 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       For patients with potential severe hypersensitivity to beta-lactam antibiotics (eg, penicillin, cephalosporin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Vancomycin*&bull;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       40 to 60 mg/kg per day in three to four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 4 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Clindamycin",
"      </td>",
"      <td>",
"       40 mg/kg per day in three divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 2.7 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       <strong>",
"        <span class=\"red\">",
"         PLUS",
"        </span>",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Levofloxacin&bull;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        6 months to 5 years: 20 mg/kg per day in two divided doses",
"       </p>",
"       <p>",
"        &ge;5 years: 10 mg/kg once per day",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 500 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Ciprofloxacin&bull;",
"      </td>",
"      <td>",
"       20 to 30 mg/kg per day in two divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 800 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       For patients with nonanaphylactic hypersensitivity to penicillin and cephalosporin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Vancomycin*&bull;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       40 to 60 mg/kg per day in three to four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 2 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Clindamycin",
"      </td>",
"      <td>",
"       40 mg/kg per day in three divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 2.7 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       <strong>",
"        <span class=\"red\">",
"         PLUS",
"        </span>",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        Aztreonam&bull;",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       90 to 120 mg/kg per day in three to four divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 8 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Meropenem&bull;",
"      </td>",
"      <td>",
"       60 to 120 mg/kg per day in three divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maximum daily dose 6 g",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Vancomycin is indicated in patients with moderate to severe sepsis, patients who may have concomitant meningitis, and patients from areas with an increased prevalence of clindamycin-resistant and/or methicillin-resistant Staphylococcus aureus isolates. Trough levels of 15-20 mcg/mL are suggested for severe infections.",
"     <br>",
"      &bull; Dosage modification for renal insufficiency is necessary. See drug information topic.",
"      <br>",
"       &Delta; A third-generation cephalosporin (ceftriaxone or cefotaxime) is preferred to ampicillin sulbactam.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25293=[""].join("\n");
var outline_f24_44_25293=null;
var title_f24_44_25294="Survival RVEF and PAP";
var content_f24_44_25294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Right ventricular dysfunction predicts poor outcome only when associated with elevated pulmonary pressures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 331px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a group of 377 patients with heart failure followed for 17 months, survival rate without urgent heart transplantation is reduced only in group 4 patients who had a reduced right ventricular ejection fraction (RVEF) associated with elevated mean pulmonary artery pressure (PAP). The survival in those with either low RVEF or high PAP was the same as those without either abnormality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ghio S, Gavazzi A, Campana C, et al. J Am Coll Cardiol 2001; 37:183.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25294=[""].join("\n");
var outline_f24_44_25294=null;
var title_f24_44_25295="Treatment of acute gout";
var content_f24_44_25295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Management of acute gout",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 487px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Adjust dose in patients with renal insufficiency.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lipsky, P. Algorithms for the diagnosis and management of musculoskeletal complaints: A new tool for the primary-care provider, (See www.swmed.edu/home_pages/cme/endurmat/ lipsky/index.html).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_44_25295=[""].join("\n");
var outline_f24_44_25295=null;
